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The NLRP3 inflammasome is a critical mediator of inflammation and consists of the 
sensor NOD-like receptor family, pyrin domain containing 3 (NLRP3), the adaptor 
apoptotic speck protein containing a caspase recruitment domain (ASC), and the effector 
caspase-1. Dysregulated or excessive activation of the NLRP3 inflammasome 
contributes to pathogenesis of diverse inflammatory diseases such as Type 2 diabetes 
and atherosclerosis. Therefore, the NLRP3 inflammasome is a promising therapeutic 
target for treating these diseases. Extracellular vesicles (EVs) are membrane-enclosed tiny 
particles released by almost any type of cells and they are involved in the intercellular 
communication by transferring their cargos including RNAs, proteins, and lipids to target 
cells. Based on their sizes, origins, and biological functions, EVs are mainly classified into 
exosomes, microvesicles and apoptotic bodies. Recently, exosome-like nanoparticles 
(ELNs) have been isolated from some edible plants, and their beneficial effects on diseases 
have also been reported. Given that mushrooms have been utilized as medicines for long 
time in some countries and they have anti-cancer, anti-inflammation and anti-microbial 
properties, we isolated ELNs from six mushrooms and tested their effects on the NLRP3 
inflammasome activation.  Among these six mushroom-derived ELNs, shiitake-derived 
ELNs (S-ELNs) significantly suppressed NLRP3 inflammasome activation and therefore 
were chosen for further study. S-ELNs were nanoparticles that contained RNAs, proteins, 
 
 
and lipids. RNA-labeled S-ELNs or lipid-labeled S-ELNs were taken up by macrophages 
in a dose-dependent manner. S-ELNs had a broad inhibitory effect on the NLRP3 
inflammasome activated by FFA, alum, nigericin, and ATP. S-ELNs inhibited assembly of 
the NLRP3 inflammasome. Importantly, we further identified lipids in S-ELNs lipids as 
active biomolecules that play an important role in suppressing NLRP3 inflammasome 
activation. Taken together, our findings suggested that S-ELNs is a promising agent that 
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CHAPTER 1. LITERATURE REVIEW 
Inflammation is important for eradication of pathogens and beneficial for the 
wound and tissue healing (1,2). There are two types of inflammation: acute inflammation 
and chronic inflammation (3). The clinical features of acute inflammation are pain, heat, 
redness and swelling (4,5). At the cellular and molecular levels, acute inflammation is 
characterized by increased permeability of the vascular, blood flow, leukocytic infiltration, 
and the release of inflammatory mediators (3,6). When the pathogens or dangerous signals 
are not eradicated completely, chronic inflammation occurs and lasts for weeks, months or 
even years (1). Chronic inflammation is mainly characterized by the development of 
immune responses at the infection site, which contributes to the pathogenesis of chronic 
diseases, including cardiovascular diseases, type 2 diabetes and renal diseases (6,7). Both 
acute and chronic inflammatory are involved in the recruitment of immune cells and the 
accumulation of inflammatory mediators, but the severity of chronic inflammation is subtle 
compared with acute inflammation (6).  
In response to infection or cellular stress, the innate immune system plays an 
important role in detecting and eliminating dangerous signals, including microorganisms 
or endogenous damage (9,8). Pattern recognition receptors (PRRs), such as Toll-like 
receptors (TLRs) and NOD-like receptors (NLRs), recognize these dangerous signals by 
sensing pathogen-associated molecular patterns (PAMPs) and damage-associated 
molecular patterns (DAMPs), leading to the recruitment of innate immune cells and the 
upregulation of proinflammatory cytokines (8). Inflammasomes, a subgroup of PRRs, are 
multiple protein complexes that are critically engaged in the immune responses to 
eradicate microorganisms and tissue repair (9). Among the inflammasomes, the NLRP3 
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inflammasome is most extensively and widely studied because it recognizes many 
DAMPs and PAMPs, and thus engaged in the chronic inflammation in many diseases 
(10). 
 The NLRP3 inflammasome consists of the sensor NOD-like receptor family, 
pyrin domain containing 3 (NLRP3), the adaptor apoptotic speck protein containing a 
caspase recruitment domain (ASC), and the effector caspase-1 (Casp1) (10,11). It can be 
activated by various stimuli, including molecules introduced during both pathogen 
infection and endogenous damage (10,11). Activation of the NLRP3 inflammasome 
results in autocleavage of Casp1 to produce Casp1 p10 and p20, which cleaves pro-
interleukin (IL)-1β and pro-IL-18 into active interleukin-1β (IL-1β) and IL-18 (10-12). 
IL-1β is one of the most important proinflammatory cytokines that plays a vital role in 
inflammatory responses (12), and engaged in various chronic inflammatory diseases, 
including type 2 diabetes and atherosclerosis (13,14).  
Under normal physiological condition, activation of the NLRP3 inflammasome 
contributes to the microorganism elimination and tissue repair (9). However, 
dysregulated or excessive activation of the NLRP3 inflammasome promotes progress of 
diverse diseases (10,11). Increasing evidence has suggested that the NLRP3 
inflammasome is a promising therapeutic target in diverse chronic inflammatory diseases 
(15). Nlrp3-/- obese mice have lower glucose levels in blood and higher insulin 
sensitivity, compared with Nlrp3+/+ obese mice (16,17). The inhibitor MCC950 that 
specifically targets NLRP3 inflammasome alleviated the severity of experimental 
autoimmune encephalomyelitis (18).  
Extracellular vesicles (EVs) are membrane-enclosed tiny particles released by 
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almost any type of cells and they are involved in the intercellular communication by 
transferring their cargos including RNAs, proteins, and lipids to target cells (19,20). EVs 
are mainly classified into three different categories based on their sizes, origins, markers 
or biological functions: exosomes (30-100 nm), microvesicles (50-2000 nm) and apoptotic 
bodies (500-5000 nm) (21). Exosomes are released from endosomal membrane through 
invagination. Exosomes are released from many mammal cells through exocytic fusion of 
multivesicular bodies with cell surface and they have been isolated from urine, plasma, 
saliva and milk (20, 25-28). Microvesicles are produced from plasma membrane through 
budding (22). Apoptotic bodies are usually larger than exosomes and microvesicles. They 
are produced during apoptosis progresses (21). However, the strict standard for EV’s 
nomenclature or classification has not been well clarified and established. Importantly, EVs 
play a significant role in both physiological and pathological processes (23). Therefore, 
they begin to serve as biomarkers or therapeutic targets in many diseases (23). In the 
physiological process, EVs secret from donor cells and deliver their cargos to recipient 
cells, thereby maintaining homeostasis such as tissue repair and immune surveillance 
(24,25). On the other hand, EVs contribute to the pathological process of some diseases 
such as Alzheimer disease and cancer (26,27).  
Recently, exosome-like nanoparticles (ELNs) have been isolated from some edible 
plants, and their beneficial effects on diverse diseases have also been reported (28-30). 
ELNs from plants share some similarity with mammal-derived exosomes: they are both 
sphere nanoparticles carrying cargos of RNAs, proteins and lipids. The exosomes from 
mammalian cells, mammalian tissues, or cow milk are often authenticated by immunoblot 
analysis of exosome-specific surface markers (31-33), but such specific surface markers of 
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ELNs from plants have not been established. Therefore, the nanoparticles isolated from 
plants are usually called exosome-like nanoparticles (ELNs) (34,35).  
Dietary exosomes or ELNs can be taken up by cells and subsequently have 
biological effects on them (34,36-38). Dietary exosomes like milk exosomes were taken 
up by mammalian cells through endocytosis (36). It was suggested that glycoproteins on 
the surface of exosomes are essential for the uptake of milk exosomes (37). The membrane-
enclosed structure of dietary exosomes or ELNs provides protection for their cargos such 
as RNAs and proteins from degradative condition of the gastrointestinal tract (39). One 
study showed that RNA cargos from milk exosomes were distributed to brain and kidneys 
in mice, which is distinctive from the distribution of the intact milk exosomes (40). 
Depletion of dietary milk exosomes could affect cognitive ability in mice, suggesting the 
important functions of milk exosomes in animals (38). Grape-derived ELNs were taken up 
by mouse intestinal stem cells, and promoted their proliferation, and therefore protect mice 
against DSS-induced colitis (30). All these findings suggest that dietary exosomes or ELNs 
have biological functions in the consumers. 
Mushrooms, which belong to Basidiomycetes and Ascomycetes, have been 
considered as one of the most nutritional foods because they are enriched in carbohydrates, 
proteins, unsaturated fatty acids, and vitamins (41). Moreover, some of mushrooms have 
been widely used for the treatment of many diseases in certain countries because of their 
medical properties including anti-inflammatory, anti-cancer, antioxidant, anti-microbial 
and anti-diabetes properties (42-47). Increasing evidence has suggested that mushrooms 
have therapeutic potential for the prevention or treatment of diseases including cancers, 
diabetes and atherosclerosis (48-50). Mushrooms play an important role in inhibiting 
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tumor growth, reducing blood glucose, enhancing immunity, and protecting against 
infection (49,51-53). A variety of bioactive compounds, including polysaccharides, 
flavonoids, phenolic compounds, terpenoids and lectins, have been identified in 
mushrooms and they are suggested to account for the medical functions of mushrooms 
(43).  
The regulatory roles of diet in the NLRP3 inflammasome activity has been reported. 
Saturated fatty acids (SFAs) including palmitate and stearate activate the NLRP3 
inflammasome and thus induce the release of IL-1β (54). However, unsaturated fatty acids 
(UFAs) including oleate linoleate, and omega-3 fatty acids suppress activation of the 
NLRP3 inflammasome, therefore reducing IL-1β secretion (55,56). Like UFAs, a variety 
of natural dietary compounds including polyphenols and flavonoids inhibit activation of 
the NRLP3 inflammasome (57,58). Hence, these studies suggest an alternative strategy of 
using natural dietary compounds or adjusting our dietary patterns for the treatment of 
chronic inflammatory diseases. Here, the NLRP3 inflammasome, the mechanism of 
NLRP3 inflammasome activation, inflammasome-related inflammatory diseases, 
extracellular vesicles in disease, functions of dietary exosomes or ELNs, effects of dietary 
molecules on activation of the NLRP3 inflammasome, and medical functions of 
mushrooms are discussed. 
1.1 NLRP3 inflammasome 
 NLRP3 is one member of the nucleotide-binding domain and leucine-rich repeat 
containing gene family (NLR) family (59). NLR family members usually serve as sensors 
for recognition of pathogens and other dangerous signals. There are  34 NLR family 
members in mice and 22 NLR family members in humans (60). The NLRs contain a N-
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terminal effector region, a centrally located nucleotide-binding-and-oligomerization 
(NOD) domain (or NACHT domains) and C-terminal leucine-rich repeats (LRRs) (60). 
The N-terminal effector region mediates downstream interactions between proteins; The 
centrally located NOD domain participates in oligomerization; The C-terminal LRRs are 
involved in stimuli recognition (60). The NLRP3 inflammasome is a multiple protein 
complex, which contains the sensor NLRP3, the adaptor ASC, and the effector caspase-1. 
ASC participates in assembly of the NLRP3 inflammasome and contains caspase 
recruitment domain (CARD) domain which is responsible for recruiting caspase-1 (61). 
Upon activation of the NLRP3 inflammasome, ASC is recruited by NLRP3, and 
subsequently forms specks in the perinuclear area of the cells. Therefore, ASC specks could 
be used as an indicator of inflammasome assembly (62-64). ASC further recruits the 
effector caspase-1 to form the NLRP3 inflammasome complex. Activation of the NLRP3 
inflammasome causes the autocleavage of caspase-1 to produce the proteolytic active 
caspase-1 p10 and p20, which cleaves pro-IL-1β and pro-IL18 into active IL-1β and IL-
18 (65,66) (Figure 1). In addition, active caspase-1 also induces pyroptosis, a specific 
type of inflammatory cell death that release DAMPs (67). Both cytokine release and 
pyroptosis are essential contributors to the inflammasome-mediated inflammatory 
process.  
1.2 Activation of the NLRP3 inflammasome 
Activation of the NLRP3 inflammasome requires two signals (68). The first signal, 
such as exogenous pathogens or endogenous molecules, induces Nlrp3 and Il1b gene 
expression through toll-like receptor (TLR) / nuclear factor (NF)- κB pathway. The second 
signal triggers the assembly of inflammasome and activation of caspase-1. The second 
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signal could be PAMPs and DAMPs, such as adenosine triphosphate (ATP), pore-forming 
toxins, and viral RNA (61) (Figure 1). Intracellular K+ efflux, reactive oxygen species 
(ROS) production, lysosomal destabilization and rupture have been suggested as upstream 
events of NLRP3 inflammasome activation (9,69).  
1.2.1 Intracellular K+ efflux 
The release of extracellular ATP triggered by cellular injury or necrosis stimulates 
K+ efflux via the purinergic P2X7 receptor and thus activates the NLRP3 inflammasome 
(70). The efflux of K+ induced by pore-forming toxin nigericin is necessary for activation 
of the NLRP3 inflammasome (71). The low intracellular levels of K+ induced by ATP and 
nigericin promote the release of IL-1β (72), while inhibition of K+ efflux suppresses the 
release of IL-1β (73), which suggests the indispensable role of K+ efflux in ATP and 
nigericin-mediated NLRP3 inflammasome activation. However, Intracellular K+ 
depletion alone is not sufficient for promoting IL-1β release (74). Furthermore, 
particulate matter activates NLRP3 inflammasome by triggering the cell membrane 
permeable to K+ (71). The release of IL-1β induced by imiquimod is not blocked by 
manipulating K+ efflux. Thus, K+ efflux might not be an upstream event for NLRP3 
inflammasome activation induced by imiquimod (75). 
1.2.2 Reactive oxygen species (ROS) production 
ROS production was suggested to serve as upstream of NLRP3 inflammasome 
activation. ROS production induced by ATP stimulates the phosphatidylinositol 3-
kinase (PI3K) signaling pathway, resulting in activation of the NLRP3 inflammasome 
and secretion of IL-1β (76). When ROS inhibitors N-acetyl-l-cysteine or (2R,4R)-4-
aminopyrrolidine-2,4-dicarboxylate were used, the secretion of IL-1β was decreased, 
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implicating that ROS production is crucial for the NLRP3 inflammasome activation 
(77). Furthermore, when RNA interference (RNAi) was used to downregulate ROS 
detoxifying proteins, the secretion of IL-1β was increased (77). NAPDH oxidases 
(NOXs) are involved in generation of ROS in cells (78). Interestingly, cells deficient in 
NOX activity exhibited the normal amounts of IL-1β secretion, but treatment of ROS 
scavengers in cells inhibited the secretion of IL-1β, suggesting ROS is required for 
activation of the NLRP3 inflammasome, and NOXs are not the only source for ROS 
production during inflammasome activation (79). Consistently, another ROS inhibitor 
diphenyliodonium also inhibits NLRP3 inflammasome activation (80).  
1.2.3 Lysosomal destabilization and rupture 
Particulate matter, also called particle pollution, is solid and liquid droplets 
suspended in air (81). A range of particulate matter (less than 1% of total particle mass) 
such as silica, asbestos and alum activate the NLRP3 inflammasome (81-83). The 
phagocytosis of particulate matter causes lysosomal swelling and rupture, release of 
lysosomal contents into cytoplasm, and subsequent NRLP3 inflammasome activation 
(82). The inhibition of phagocytosis impaired NRLP3 inflammasome activation in 
response to particulate matter (82). The H+ ATPase inhibitor, which blocked lysosomal 
acidification, attenuated NLRP3 inflammasome activation (82). The inhibition of 
lysosomal protease also reduced activation of the NLRP3 inflammasome (82). These 
studies indicated that lysosomal destabilization is required for the particulate matter-
induced NLRP3 inflammasome activation. 
1.3 Role of NLRP3 inflammasome activation in diseases 
The NLRP3 inflammasome plays an important role in inflammatory responses 
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and is incriminated in the pathogenesis of many metabolic diseases, including type 2 
diabetes, atherosclerosis and liver disease.   
1.3.1 Type 2 Diabetes  
The NLRP3 inflammasome contributes to the progression of type 2 diabetes (84). 
IL-1β, one downstream of NLRP3 inflammasome activation, induces the inflammation 
in pancreatic islets, which leads to the destruction of β-cells, and therefore reduces 
insulin production (85). Also, IL-1β leads to insulin resistance and affects the glucose 
uptake (86). Increased macrophage infiltration has also been found in the pancreatic 
islets of patients with type 2 diabetes (87). Knockout of NLRP3 in mice protected 
pancreatic β-cells from damage and thus these mice had increased insulin levels in the 
blood (17). The antidiabetic drug glyburide was shown to inhibit NLRP3 inflammasome 
activation (88,89). TXNIP inhibitor, which inhibited the NLRP3 inflammasome 
activation, enhanced glucose tolerance and insulin sensitivity in mice (16).   
1.3.2 Atherosclerosis 
Atherosclerosis has been considered as an inflammatory disease and is 
characterized by the accumulation of lipids, cholesterol, and other substances in the 
artery wall (90). Cholesterol metabolism is tightly linked with inflammation in 
atherosclerosis (91).  Cholesterol crystals are accumulated in atherosclerotic lesions and 
trigger activation of the NLRP3 inflammasome and thus lead to IL-1β release from 
macrophages in the lesions (92). The level of IL-1β is correlated with the severity of 
atherosclerosis (92). IL-1β deficiency decreased the severity of atherosclerosis in 
apolipoprotein E (ApoE) knockout mice (93). Similarly, knockdown of the Nlrp3 gene 
in ApoE knockout mice showed lower levels of proinflammatory cytokines, less 
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macrophage infiltration in the atherosclerotic lesions, and overall less severity of 
atherosclerosis induced by hyperhomocysteinemia (94). Silencing the Nlrp3 gene or 
using caspase-1 inhibitor blocked homocysterine-induced NLRP3 inflammasome 
activation in macrophages (94). In addition, when RNAi was used to silence the sensor 
NLRP3, cholesterol crystal-induced IL-1β secretion were decreased, suggesting the 
important role of NLRP3 inflammasome in cholesterol crystal-induced inflammation 
(95).  
1.3.3 Liver disease 
IL-1 β secreted by macrophages (Kupffer cells) in liver is key driven for alcohol-
induced liver inflammation, steatosis, and damage, because IL-1 receptor antagonist 
significantly attenuates this alcoholic hepatitis (96). The hepatocytes damaged by 
alcohol release DAMPs, which activate the NLRP3 inflammasome in Kupffer cells  (97). 
When a mutant form of Nlrp3 gene resulting in a hyperactive NLRP3 was introduced in 
mice, these knock-in mice show severe inflammation, fibrosis in liver and remarkable 
hepatocyte pyroptotic cell death (98). Sulforaphane, which inhibits activation of the 
NLRP3 inflammasome through AMP-activated protein kinase-autophagy axis, 
attenuates hepatic steatosis in high fat diet-treated mice (99). Therefore, strategies that 
inhibit IL1-β and NLRP3 inflammasome activation could have high therapeutic 
potential to treat liver disease. 
1.4 Extracellular vesicles 
Extracellular vesicles (EVs) are phospholipid bilayer-enclosed tiny particles 
released from eukaryotic and prokaryotic cells (19,20). Almost all the cell types, such 
as T cell, dendritic cells, tumor cells, stem cells and endothelial cells, release EVs (23). 
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EVs have been found in urine, saliva, blood plasma and breast milk (100-103). Based 
on their sizes, origins, surface markers, and biological functions, EVs are mainly 
classified into exosomes, microvesicles and apoptotic bodies (20-22,104). 
Ultracentrifugation, immunoaffinity and chromatography are typical approaches to 
isolate EVs and subtypes of EVs can be isolated using different approaches (105). EVs 
are recognized to transfer biological information between cells by carrying cargos of 
RNAs, proteins and lipids (106). Importantly, EVs play a key role in both physiological 
and pathological processes (19, 107).  
1.4.1 Content of EVs 
A variety of techniques have been used to characterize protein composition of 
EVs, including mass spectrometry-based proteomics, western blotting, enzymatic 
activity and serological reactivity (108,109). Some of proteins in EVs could serve as 
biomarkers for diseases detection or targets of immunotherapies (110). CD63, CD9, 
CD81, MHC I, MHC II, Gp96, Actinin-4, Tsg 101, heat-shock proteins 70 have been 
identified as common surface biomarkers of EVs and some of them are specific surface 
markers for some subgroups of EVs (111). In addition to the proteins, EVs are enriched 
with RNAs, including mRNAs, miRNAs, rRNAs and tRNA fragments (112-114). Most 
of the RNAs in EVs are very short and fragmented (115). RNAs delivered to the 
recipient cells are actually functional (116). miRNAs in dendritic cell-derived exosomes 
downregulate target genes in recipient dendritic cells (117). miR-155 encapsulated in 
exosomes was delivered to cardiac fibroblasts and inhibited proliferation of these cells 
(118). miR-135b in hypoxia-resistant multiple myeloma cell-derived exosomes 
increased endothelial tube formation (46). Like proteins, miRNAs in EVs can be used 
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as biomarkers for disease diagnosis or therapy because specific miRNAs could be 
aberrantly enriched in EVs under certain pathological conditions (119,120). Exosomal 
miR-1290 and miR-375 have been studied as promising biomarkers in diagnosis of 
castration-resistant prostate cancer (121). EVs display a specific lipid composition and 
organization (122). Usually glycosphingolipids, sphingomyelin, cholesterol and 
phosphatidylserine are highly enriched in most EVs, indicating an important role of 
these lipids in EVs biogenesis (123). These lipids contribute to the stability and 
structural rigidity of EVs (124,125). Phosphatidylserine on the surface of exosomes is 
thought to be an intercellular signaling, which can be recognized by Tim4 receptors on 
the macrophages (126).  
1.4.2 Physiological and pathological role of EVs 
EVs are engaged in a variety of physiological and pathological processes by 
mediating intercellular communication (127). Direct cell-cell communication is often 
achieved through membrane surface molecules (128). In contract, EVs mediate 
intercellular communication through their cargos of protein, RNAs, and lipids (106). 
After EVs are taken up by recipient cells, their cargos are released and thus mediate the 
functions of target cells (129). EVs are involved in stem cell maintenance, tissue repair, 
immune surveillance, and blood coagulation (130). EVs from embryonic stem cells 
deliver mRNA to recipient stem cells to increase their pluripotency (107). Microvesicles 
released from mesenchymal stem cells inhibited apoptosis and promoted proliferation 
of tubular epithelial cells, thereby protecting rats from acute kidney injury (131). 
Exosomes released from B lymphocytes induce T cell responses (25). EVs released from 
hepatocytes transferred RNAs to liver stellate-like cells and activate their proliferation 
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(132). EVs released from neurons represent a novel way for inter-neuronal 
communication, as specific neuron-derived EVs directly regulated signal transduction 
and protein expression in target neurons cells (133). 
Exosomes released from dendritic cells regulate the inflammatory response by 
regulating inflammatory gene expression in recipient dendritic cells (134). Exosomes 
derived from FasL-expressing dendritic cells inhibit inflammation in a murine arthritis 
model (135). This study indicated that these specific exosomes may have the therapeutic 
potential to treat arthritis (135). LPS-stimulated macrophage-derived exosomes have an 
immunoprotective role, because an intraplantar injection of these exosomes reduced paw 
thickness and thermal hypersensitivity in a mouse model of inflammatory pain (136).  
Exosomes from body fluids of ovarian cancer patients have immunomodulatory 
capacities because they trigger the gene expression of NF-κB- and STAT3-mediated 
cytokines in monocytic precursor cells (137). Exosomes released from adipose-derived 
stem cells increased insulin sensitivity, reduced weight and attenuated hepatic steatosis 
in obese mice (138). Donor mouse-derived peripheral exosomes inhibited the 
inflammation of the allograft heart in recipient mice by inducing Treg cells, which 
potently suppress immune responses (139). 
Because EVs transfer biological information between cells, it is possible that 
EVs also transfer disease-driven factors between cells to spread diseases. EVs isolated 
from parasite-infected host cells or plasma contain both host and parasite molecules, 
disseminate the pathogens, and regulate the host immune systems (140). EVs participate 
in the pathogenesis of various diseases, including osteoarthritis, atherosclerosis, 
thromboembolism, chronic renal disease, pulmonary hypertension, periodontitis, gastric 
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ulcers and bacterial infections (141). Tumor-derived EVs deliver causative molecules 
such as microRNAs or oncogenes to recipient cells, resulting in the change of biological 
functions, gene expression pattern, and overt tumorigenic conversion in recipient cells  
(142). The levels of EVs are increased in atherosclerotic lesions and they may lead to 
the progress of atherosclerosis (143). The level of plasma EVs is higher in patients with 
cardiovascular diseases compared with healthy individuals. Therefore the circulating 
EVs could be used as a prognostic marker for diagnosis of cardiovascular (144). EVs 
cause extracellular matrix degradation and inflammation by carrying catabolic proteases, 
antigens and miRNA, thus contributing to the pathophysiology of osteoarthritis and 
rheumatoid arthritis (145). Given the fact that EVs mediate disease pathogenesis, the 
potential use of EVs as diagnostic and therapeutic biomarkers has been explored in 
various diseases. Developmental endothelial locus-1 protein in circulating EVs is a 
promising biomarker, which could be potentially used to identify early-stage breast 
cancer (146). Specific miRNA in salivary exosomes has the potential to be utilized as a 
biomarker for diagnosis of salivary gland diseases such as Sjögren’s syndome (102). 
1.5 Dietary exosomes or exosome-like nanoparticles (ELNs) 
Dietary exosomes or ELNs have been demonstrated to participate in interspecies 
communication (34). For example, grape-derived ELNs induced Lgr5hi intestinal stem 
cells and by doing so protected mice from DSS-induced colitis (30). Grapefruit-derived 
ELNs attenuated DSS-induced colitis by inhibiting the production of IL-1β and Tumor 
necrosis factor-α (TNF-α), suggesting their immune modulatory role in colitis (147). In 
addition, grapefruit-derived ELNs have been utilized as a nano-vector to deliver 
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therapeutic compounds to tumor sites (148). Compared with synthetic nanoparticles, 
grapefruit-derived ELNs do not cause cytotoxic reactions (149).  
Besides grape-derived and grapefruit-derived ELNs, milk exosomes gain 
extensive interest. The exosome surface markers such as MHC, CD63, CD81 and CD86 
are detectable in exosomes isolated from human breast milk, and these exosomes inhibit 
the release of interleukin-2 (IL-2) and interferon- γ (IFN-γ), suggesting the immune 
regulatory functions of these exosomes (103). Immune-related miRNAs are found in 
breast milk exosomes and can be transferred to infants and thereby affect the 
development of infant immune system (150). Bovine milk exosomes (BMEs) are taken 
up by human and rate intestinal cells through endocytosis and glycoproteins on the 
surfaces of exosome play important role in uptake of BMEs (151). The bioactivity of 
BMEs has been demonstrated in vivo and in vitro. BMEs deliver miRNAs into 
macrophages and therefore alter gene expression of inflammatory cytokine such as IL-
1, IL-6 and IL-10, and increase phagocytosis (152). Depletion of BMEs in the mouse 
diet not only alters the gene expression pattern and the profiles of amino acid in skeletal 
muscle of mice, but also alters their microbial communities in gut, suggesting that BMEs 
facilitate the interspecies communication among cow milk, host, and microbiomes 
(153,154). Compared with the distribution of intact BMEs, the distribution of specific 
miRNA cargoes from BMEs has a distinct pattern in mice (155). Intact BMEs are mainly 
accumulated in liver, spleen and brain, while their fluorescence-labeled microRNA 
cargos distribute in intestinal mucosa, heart, liver, spleen and brain (155). BMEs 
regulate lung inflammatory responses through promoting M1 macrophage polarization 
and increasing the levels of IL-6 and TNF-α (156). BMEs were used for the delivery of 
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chemotherapeutic/chemopreventive agents in mice and did not cause adverse immune 
and inflammatory response (157). Therefore, BMEs have high potential to serve as a 
drug delivery platform.  
1.6 Effects of dietary molecules on activation of the NLRP3 inflammasome 
1.6.1 Saturated fatty acids 
Many foods are abundant in saturated fatty acids (SFAs), including fast foods, 
meats and dairy products (158). Dietary SFAs trigger NLRP3 inflammasome activation 
in adipocytes and macrophages via several possible mechanisms, including JNK 
signaling pathways, toll-like receptor 2/4 (TLR 2/4) (159-162), or an AMPK-autophagy-
ROS signaling pathway (163). It was also suggested that SFAs-induced NLRP3 
inflammasome activation involves in Na, K-ATPase disruption and K+ efflux (164). 
SFAs such as free fatty acids (FFAs) activate the NLRP3 inflammasome and result in 
IL-1β secretion, which inhibits insulin signaling through serine-threonine kinase 
phosphorylation and thereby leads to insulin resistance (163). A recent study shows that 
the reduction of inter-endothelial tight junction proteins ZO1/2 and increased 
permeability of endothelial monolayers were associated with FFAs-induced NLRP3 
inflammasome activation because these impairments were reversed by NLRP3 
inflammasome-related inhibitors such as HMGB1 inhibitor and lysosomal cathepsin B 
inhibitor (165). Palmitate (PA), a long-chain SFA, activates NLRP3 inflammasome and 
thus promotes inflammatory responses in cardiac fibroblasts (55). A new mechanism of 
SFA-induced NLRP3 inflammasome activation was proposed recently. SFAs became 
crystallized inside of  macrophages, subsequently caused lysosomal dysfunction, and 
therefore led to activation of the NLRP3 inflammasome (54).  
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1.6.2 Unsaturated fatty acids 
Unlike SFAs, unsaturated fatty acids (UFAs) inhibit NLRP3 inflammasome 
activation in macrophages or monocytes (55). UFAs improve insulin resistance by 
reducing NLRP3 inflammasome-dependent IL-1β secretion in high fat diet (HFD)-
induced obese mice (166). Fish oil enriches in omega-3 polyunsaturated fatty acids 
(PUFAs), which are beneficial for human health. Interestingly, omega-3 PUFAs also 
inhibit activation of the NLRP3 inflammasome and reduce transient expression of the 
Il1b gene in peripheral blood mononuclear cells (167-169). In the traumatic brain injury 
model, omega-3 PUFAs prevented mitochondrial localization of the sensor NLRP3 and 
by doing so inhibited NLRP3 inflammasome activation and reduced IL-1β secretion 
(170). Omega-3 PUFAs downregulated expression of inflammatory genes including 
Nlrp3 and Il1b genes in adipocytes and monocytes/macrophages stimulated with LPS 
plus INF-γ (171). IL-1β secretion and caspase-1 autocleavage were reduced in 
macrophages and hepatocytes from dietary PUFAs-fed mice and it seems that dietary 
PUFAs attenuated NLRP3 inflammasome activation through increasing autophagy 
pathway (172). 17-oxo-DHA, a derivative of omega-3 fatty acids Docosahexaenoic acid 
(DHA), inhibited NLRP3 inflammasome activation through suppressing mROS production 
and ERK signaling in macrophages (173).  
1.6.3 Other dietary components 
Components extracted from various foods have anti-inflammatory properties. 
Some of them inhibit activation of the NLRP3 inflammasome, though the underlying 
mechanism is poorly understood. Epigallocatechin-3-gallate (EGCG) is a polyphenolic 
component extracted from green tea. It has been shown that EGCG inhibited expression 
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of Nlrp3 gene in mice with lupus nephritis (174). Another polyphenolic compound from 
turmeric called curcumin inhibited caspase-1 autocleavage and IL-1β secretion upon 
NLRP3 inflammasome activation, possibly by suppressing K+ efflux (175). Purple 
sweet potato color (PSPC) is a flavonoid extracted from purple sweet potato. It inhibited 
NF-kB nuclear translocation and NLRP3 inflammasome activation, and therefore 
protected high-fat diet mice against hepatic inflammation (176). Fruits enriched in 
procyanidins, such as grapes, have been reported to have inhibitory effects on 
inflammatory response and inflammatory diseases (177,178). Later, Yang group 
revealed that procyanidin blocked the transcriptional activity of activator protein-1 
pathway, which led to the inhibition of ROS production, and subsequently suppressed 
NLRP3 inflammasome activation in endothelial cells (57). Mangiferin isolated from 
mangos inhibited activity of the transcription factor NF-kB, which regulates 
transcription of many inflammatory genes including cytokines and chemokines (179). 
Magniferin also inhibited NLRP3 inflammasome activity. As a result, Mangiferin 
alleviated severity of some diseases including mastitis, traumatic brain injury and liver 
injury (180-183). Resveratrol is enriched in fruits such as grapes, raspberries, 
blueberries and mulberries (184). Resveratrol treatment helped to maintain 
mitochondrial integrity, reduce the mROS production and therefore attenuate activation 
of the NLRP3 inflammasome (185,186). Sulforaphane, a compound enriched in broccoli, 
inhibited NLRP3 inflammasome activation and ameliorated Ischemia/reperfusion injury 
and acute gout in animal models (187,188). It was demonstrated that Taiwanese green 
propolis suppressed NLRP3 inflammasome activation and its bioactive compound called 
propolin G likely mediated this inhibitory effect (189). In summary, these dietary 
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components represent a novel and alternative strategy to inhibit activation of the NLRP3 
inflammasome and thus curb or treat chronic low-grade inflammation in a variety of 
diseases. 
1.7 Medical functions of mushrooms 
1.7.1 Anti-inflammatory property 
Mushrooms have been reported to have anti-inflammatory functions. A 
mushroom called Huaier (Trametes robiniophila Murr.) inhibited NLRP3 
inflammasome activation via the autophagy-lysosome degradation pathway, and 
therefore attenuated symptoms of DSS-induced colitis (190). Glucans extracted from 
Indian oyster (Pleurotus pulmonarius) also suppressed inflammation in DDS-induced 
colitis, suggesting its potential role in the treatment of inflammatory bowel disease (191). 
Ergosterol peroxide (a bioactive compound found in hen of the woods (Grifola 
frondosa)), cauliflower mushroom (Sparassis crispa) and lingzhi mushroom 
(Ganoderma lucidum), suppressed cytokine production by inhibiting mitogen-activated 
protein kinases (MAPKs) signaling pathways or NF-κB signaling in macrophages (192-
194). Oyster mushroom (Pleurotus ostreatus) also showed anti-inflammatory function 
because it suppressed TNF-α and IL 6 secretion both in vitro and in vivo (195). Addition 
of portobello (Agaricus bisporus) and shiitake mushrooms (Lentinula edodes) in the diet 
protected Ldlr-/- mice from high-fat diet-induced atherosclerosis (50).  
1.7.2 Anti-cancer property 
The anti-cancer property of mushrooms has been widely studied. A protein FVE 
isolated from Enoki mushroom (Flammulina velutipes) and grifolin isolated from Sheep 
Polypore mushroom (Albatrellus confluens) and white button mushroom (Agaricus 
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bisporus) inhibited tumor growth, indicating that these mushrooms contain anti-tumor 
agents (51,196,197). In most cases, mushrooms induce apoptosis of cancer cells. For 
example, Chaga mushroom (Inonotus obliquus), lection isolated from Kurokawa 
mushroom (Boletopsis leucomelas), and grifolin isolated from Sheep Polypore 
mushroom (Albatrellus confluens) are all capable of inducing apoptosis of cancer cells  
(197-199). Some studies have demonstrated that some of the mushrooms or their extracts, 
such as willow bracket (phellinus igniarius) and polysaccharide lentinan from shiitake 
mushroom (Lentinus edodes) caused cell cycle arrest at G0/G1 phase and prevented 
tumor cell proliferation (200,201). White button mushroom (Agaricus bisporus) 
inhibited the proliferation of both prostate cancer cells and breast cancer cells (51,202). 
Song gen mushroom (Phellinus linteus) caused either cell-cycle arrest or apoptosis in 
lung cancer cells depending the dosage used, suggesting it has an anti-cancer effect (203). 
Ergosterol peroxide isolated from Chaga mushroom (Inonotus obliquus) inhibited 
proliferation of colon cancer cells in vitro and tumor growth in mice (204).  
1.7.3 Other properties 
Besides anti-inflammatory and anti-cancer properties, mushrooms also show 
other beneficial effects such as enhancement of immunity, antioxidant function, and 
anti-microbial function (204-206). Mushrooms enhance immunity through stimulating 
natural killer cell or increasing IFN γ and TNFα secretion (207). Consumption of dried 
shiitake mushroom (Lentinus edodes) enhanced immunity in humans by promoting 
proliferation of gamma delta T (γδ-T) cells and natural killer T (NK-T) cells and 
increasing secretory immunoglobulin A in saliva (208). Lectin isolated from mushroom 
Fomitella fraxinea has an immunomodulatory function. It increased major 
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histocompatibility complex (MHC)-restricted antigen presentation and protected 
chicken from coccidiosis (52,209). Oyster mushroom (Pleurotus ostreatus) extracts 
protected rats from CCl4-induced liver injury by decreasing the levels of liver-related 
enzymes, including glutamic oxaloacetic transaminase, alkaline phosphatase and 
glutamic pyruvate transaminase, and improved antioxidant activity of liver by increasing 
antioxidant activity-related enzymes, such as catalase, glutathione peroxidase and 
superoxide dismutase (210). Extracts (using ethanol) from crab-of-the-woods mushroom 
(Laetiporus sulphureus), extracts (using water, methanol, acetone, and ethyl acetate) 
from Enoki mushroom (Flammulina velutipes), white and brown shimeji variants 
(Hypsizygus tesselatus) inhibited the growth of bacteria. These findings suggest that 
these mushrooms contain antimicrobial agents, which could be potentially used for the 
treatment of infection (46,211). Extracts (using water) from Almond mushroom 
(Agaricus blazei Murill) protected mice against streptococcus pneumoniae infection 
(53). 
1.8 Conclusion 
The NLRP3 inflammasome is a multiprotein complex that consists of the sensor 
NLRP3, the adaptor ASC, and the effector caspase-1. Both endogenous DAMPs or 
exogenous PAMPs can trigger NLRP3 inflammasome activation, thereby leading to 
caspase-1 autocleavage and subsequent IL-1β secretion. Several models have been 
proposed to explain how NLRP3 inflammasome activation is triggered. Intracellular K+ 
efflux, ROS production, lysosomal destabilization and rupture were indicated as the 
upstream events of NLRP3 inflammasome activation. Dysregulated activation of the 
NLRP3 inflammasome is involved in a variety of chronic diseases, such as type 2 diabetes, 
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atherosclerosis and liver disease. EVs are phospholipid bilayer-enclosed tiny particles 
released from eukaryotic and prokaryotic cells. They play an important role in 
intercellular communication and even interspecies communication by delivering and 
releasing cargos such as microRNAs in the target cells. Exosomes, a subtype of EVs, 
are nanoparticles that contain lipids, RNAs, and proteins. Dietary exosomes or exosome-
like nanoparticles (ELNs) are taken up by consumers, distributed in different tissues, 
and have bioactive functions in animal models. Mushrooms have showed a range of 
medical benefits to human health and therefore their bioactive components represent 
promising candidates for the treatment of diseases. Therefore, in our studies, we aimed 

















CHAPTER 2. EXPERIMENTS AND RESULTS 
2.1 Introduction 
The NLRP3 inflammasome is a multiprotein complex composed of NLRP3, ASC 
and caspase-1 (10,11). A variety of exogenous PAMPs or endogenous DAMPs stimulate 
the NLRP3 inflammasome, leading to caspase-1 autocleavage and IL-1β and IL18 
secretion (65). Activation of the NLRP3 inflammasome requires two signals: the first 
signal stimulates expression of the Nlrp3 and Il1b genes; the second signal causes the 
assembly of inflammasome complex, which activates the autocleavage of caspase-1 to 
produce caspase-1 p10 and p20, and then cleave pro-IL-1β and pro-IL18 to generate active 
IL-1β and IL 18 (65). IL-1β is a major cause of acute and chronic inflammation and thus 
involved in the pathological processes of various inflammatory diseases (212). Therefore, 
activation of the NLRP3 inflammasome contributes to the pathogenesis of these diseases. 
Emerging evidence demonstrates that inhibition of the NLRP3 inflammasome suppresses 
the secretion of IL-1β, and therefore improves the conditions of chronic inflammatory 
diseases, including diabetics, Alzheimer’s disease and gout (213-215). In short, the NLRP3 
inflammasome is suggested to be a promising therapeutic target for treatment of NLRP3 
inflammasome-related diseases. 
Exosomes are biolayer membrane-enclosed nanoparticles released from cells (20). 
They participate in intercellular communication and even interspecies communication by 
delivering and releasing their cargos of RNAs, proteins and lipids to target cells, thereby 
regulating the bioactivity of target cells, including gene expression and functions (106). 
Dietary exosomes or exosome-like nanoparticles (ELNs) have been obtained from diet 
sources.  A variety of dietary ELNs have been identified from edible plants such as ginger, 
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carrots, grapefruit and grapes (34). In particular, dietary ELNs have therapeutic potential 
for the treatment of diseases (30). Mushrooms have been utilized as medicines in certain 
countries because of their anti-inflammatory, anti-cancer, antioxidant and anti-microbial 
properties (42-47). We are highly interested in mushrooms due to their medical properties. 
To the best of our knowledge, mushroom-derived ELNs have never been studied and the 
effects of  mushroom-derived ELNs on NLRP3 inflammasome activation has never been 
evaluated.  
In this study, shitake mushroom-derived ELNs (S-ELNs) were isolated and 
characterized for the first time. We discovered the inhibitory effects of S-ELNs on NLRP3 
inflammasome activation in macrophages. Furthermore, we identified that lipids in S-
ELNs as active biomolecules that suppressed NLRP3 inflammasome activation. 
Collectively, S-ELNs represent a promising agent that blocks NLRP3 inflammasome 
activation. 
2.2 Central Hypothesis, Purpose, and Specific Aims 
A. Purpose of the Study 
The purpose of the study is to investigate the effects of S-ELNs on the NLRP3 
inflammasome activation in bone marrow-derived macrophages (BMDM) and identify 
active biomolecules in S-ELNs with anti-inflammasome functions.  
B. Central Hypothesis 
S-ELNs inhibit NLRP3 inflammasome activation in macrophages. 
C. Specific Aims 
Specific Aim 1: Evaluate the effects of S-ELNs on NLRP3 inflammasome activation. 
Specific Aim 2: Identify which category of cargos (RNAs, proteins and lipids) is the active 
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biomolecules that inhibit the NLRP3 inflammasome in macrophages. 
2.3 Materials and Methods 
2.3.1 Preparation of S-ELNs 
Mushrooms were washed with water and gently dried using tissues. After washing, 
mushrooms were weighted and cut into small pieces. The mushroom pieces were put in 
cold phosphate buffered saline (PBS) and homogenized in a kitchen blender for 15 seconds. 
The juice was collected and centrifuged at 500g, 10 minutes 4 ℃ and then at 2000g, 20 
minutes, 4 ℃, respectively. The juice was then collected and ultracentrifuged at 10,000g, 
30 minutes, 4 ℃ and at 100,000g, 2 h, 4 ℃, respectively. The pelleted ELNs were 
resuspended in 2 ml PBS and passed through a  0.45 m filter and then 0.2 m filter. The 
concentration of ELNs was measured using the Nanosight NS300 machine (Malvern 
Panalytical). 
2.3.2 RNA depletion of S-ELNs 
0.2 µl RNase (10 ng/ml) was added to 200 µl S-ELNs (3.55*1012 /ml). The solution 
underwent bath sonication for 90 minutes at room temperature using a bath sonication 
machine (Branson CPX5800H). After sonication, the solution was incubated at 37 ℃ water 
bath for another 1 h.  
2.3.3 Liposome preparation 
Lipids in S-ELNs were extracted based on the Folch method (30). 1000 µl S-ELNs 
(1.12*1012 /ml) were added to 3800 µl mixture of CHCl3 (1267 µl) : MeOH (2533 µl) at a 
1:2 ratio (v/v) and vortex. An aliquot (1267 µl) of CHCl3 was added to the mixture. The 
mixture was vortexed and stirred vigorously for 1 h. After stirring, 1267 µl molecular water 
was added to the mixture. The mixture was vortexed and stirred vigorously for another 1 
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h. The mixture was centrifuged at 2,000 g for 10 minutes at room temperature, and then 
organic phase containing lipids was collected. The organic phase was dried under nitrogen 
gas (0.2-0.5 psi) at 60 ℃. Dried lipids were suspended in 200 µl molecular water, and 
subsequently sonicated for 5 minutes. 200 µl buffer (40 mM HEPES, 308 mM NaCL, Ph 
7.4) was added and sonicated for another 5 minutes to obtain liposomes. The liposomes 
were used immediately or stored at – 80 ℃. 
2.3.4 Scanning electron microscopy (SEM)  
S-ELNs were purified using sucrose gradient methods. 1000 µl crude S-ELNs were 
added on top of sucrose gradient with density of 2M, 1.8M, 1.6M, 1.4M, 1.2M, 1M, 0.8M, 
0.6M, 0.4M, 0.2M and then were ultracentrifuged at 100,000g, 12 h, 4 ℃. The layer 
contains S-ELNs was collected and fixed with glutaraldehyde (final concentration 2.5%, 
EMS#16320) for 30 minutes at room temperature. Subsequently, S-ENLs were fixed with 
tannic acid (final concentration 1%, EMS#21700) for 30 minutes at room temperature. 
After fixation, S-ELNs were loaded on the Nucleopore track-etched membrane (100 nm 
pore size, Whatman), dried overnight, and sputter-coated using a Desk Vsputter (Denton 
Vacuum InC). S-ELNs were visualized using scanning electron microscope (Hitachi S4700 
FE). 
2.3.5 Agarose gel, SDS-PAGE gel and Thin-layer Chromatography (TLC) analysis 
Total RNAs were extracted from S-ELNs using commercial miRNeasy mini kit 
(Qiagen). 700 µl QIAzol lysis reagent was added to S-ELN pellets. The RNAs were eluted 
in 30 µl RNase-free molecular biology grade water (Corning). 400 ng RNAs were loaded 
into 2% agarose gels to separate. Proteins extracted from S-ELNs were separated using 
SDS-PAGE gels (Novex) and gels were stained using Coomassie Brilliant Blue. Lipids 
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were extracted from S-ELNs using the Folch method mentioned above. The lipids were 
separated on the thin-layer chromatography (TLC) plate (Millipore Sigma) using a solvent 
system (chloroform : methanol : acetic acid at a ratio of 190:9:1, v/v/v) and visualized using 
CuSO4 phosphric acid solution. 
2.3.6 Macrophage cell culture and ELNs treatment 
Mouse bone marrow-derived macrophages (BMDMs) were cultured using the bone 
marrow cells from the femurs and tibias of C57BL/6 mice. The bone marrow cells stored 
at -80 ℃ were thawed and cultured in growth media (61% RPMI 1640 media (Corning), 
1% sodium pyruvate (Corning), 1% L-glutamine (Corning), 1% penicillin/streptomycin 
(Corning), 1% HEPES (Corning), 25% L929 media and 10% fetal bovine serum (FBS, 
Atlanta Biologicals)). Cells were incubated at 37 ℃ in 5% CO2 for 6-8 days until a uniform 
monolayer of macrophages was established. Macrophages were split and seeded into a 12-
well plate with growth media overnight. The culture media were changed to plating media 
(76% RPMI 1640 media (Corning), 1% sodium pyruvate (Corning), 1% L-glutamine 
(Corning), 1% penicillin/streptomycin (Corning), 1% HEPES (Corning), 10 % L929 media 
and 10% precleared-fetal bovine serum (FBS, Atlanta Biologicals)). 4 h later, S-ELNs were 
added to cells. After 16 h S-ELN incubation, Lipopolysaccharide (LPS (10 ng/ml), 
InvivoGen, tlrl-peklps) was added to cells and incubated for 3 h. Free fatty acid sodium 
palmitate (FFA) (Sigma) was added to cells and incubated for another 12 h. The culture 
medium was collected and centrifuged at 300 g, 5 minutes, 4℃ to remove cells and big 
cell debris. The precleared culture medium was used to measure IL-1β release using ELISA 
kit (eBioscience). The cell lysates were collected using Sodium Dodecyl Sulfate (SDS) 
lysis buffer and subject to western blot to measure capase-1 autocleavage. Macrophages 
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were also stimulated using Alum (Thermo Scientific), nigericin (Enzo Life Sci) or ATP 
(Sigma) to activate the NLRP3 inflammasome. 
2.3.7 ELISA and western blot 
The level of IL-1β in the culture medium was measured using ELISA kit 
(eBioscience). Proteins in cell lysates were separated using 4-12% SDS-PAGE gels 
(Novex) and transferred into polyvinylidene difluoride (PVDF) membrane (0.45 µm, GE 
Healthcare). Primary antibodies against tubulin, caspase-1 p10, pro-IL-1β, ASC, NLRP3 
and Nek7 were used to incubate with membrane overnight. The secondary antibodies 
including anti-rabbit-HRP, anti-mouse-HRP or anti-goat-HRP (Cell Signaling) were used 
to detect the levels of proteins. Tubulin antibody was purchased from Santa Cruz 
Biotechnology. Primary antibodies against NLRP3, ASC, caspase-1 p10 were purchased 
from Adipogen. Primary antibody against Nek7 was purchased from Abcam. Anti-pro-IL-
1β antibody was purchased from R&D systems. 
2.3.8 Uptake studies of S-ELNs 
RNAs in S-ELNs were labeled using ExoGlowTM-RNA EV labeling kit (SBI 
System Biosciences). 8.3 µl S-ELNs (1.83 *1012 /ml) were added to incubation buffer to 
make a 50 µl solution. 3 µl ExoGlow RNA probe was added to the mixture and then the 
mixture was incubated at 37 ℃ 1 h in dark. The mixture was added into 35 ml PBS and 
ultracentrifuged at 100,000g, 2 h to remove free probes. The pellet of RNA-labeled S-ELNs 
was suspended in 2 ml PBS. Lipids in S-ELNs were labeled using DiI dye (Thermo Fisher 
Scientific) as per manufacturer’s protocol. After labeling, the mixture was added into 35 
ml PBS and ultracentrifuged at 100,000g, 2 h to remove free DiI dye. The pellet of lipid-
labeled S-ELNs was suspended in 2 ml PBS.  
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Glass coverslips were pre-plated in a 24-well plate, and then macrophages were 
seeded and cultured using growth media overnight. 4 h before S-ELNs were added to cells, 
the culture medium was changed to plating medium. RNA-labeled or lipid-labeled S-ELNs 
were added to macrophages. After 16 h incubation, macrophages were washed with PBS 
for 3 times and fixed with 4% paraformaldehyde (Sigma) on ice for 20 minutes. After 20 
minutes, macrophages were washed with PBS for 3 times. Nucleus was subsequently 
stained using DAPI (Fisher Scientific). The uptake of fluorescence-labeled S-ELNs by 
macrophages was evaluated using a confocal fluorescence microscope (Nikon A1R). 
2.3.9 ASC speck detection 
Glass coverslips were pre-plated in a 24-well plate, and then macrophages were 
seeded and cultured using growth media overnight. The culture medium was changed to 
plating media. 4 h later, S-ELNs were added to cells. After 16 h incubation, macrophages 
were incubated with LPS (10 ng/ml) for 3 h, followed by incubation of caspase-1 inhibitor 
VX765 (10 µM) for 0.5 h. Finally macrophages were stimulated with FFA for 12 h. After 
12 h incubation, macrophages were washed with PBS for 3 times and fixed with 4% 
paraformaldehyde (Sigma) on ice for 20 minutes. After 20 minutes, macrophages were 
washed with PBS for 3 times. Rabbit anti-ASC antibody (Adipogen) was used to incubate 
with macrophages overnight at 4 ℃. Secondary antibody anti-rabbit Alexa Fluor 594 
(Invitrogen) was used. Nucleus were stained using DAPI (Fisher Scientific). 
Immunofluorescence was detected using a confocal microscope (Nikon A1R). 
2.3.10 RNA extraction and real time quantitative polymerase chain reaction (qPCR) 
          Macrophages were treated with S-ELNs for 16 h, incubated with LPS for 3 h, and 
then activated with FFA for 12 h or ATP for 0.5 h. mRNAs were extracted from 
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macrophages using RNA bee (Tel-Test) and then the concentration of mRNA was 
measured. 1 µg mRNAs were used for cDNA synthesis using High-Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems). Quantitative polymerase chain reaction 
(qPCR) was performed to assess expression of the genes including Nlrp3, Caspase1, 
Pycard and Il1b using a real time qPCR machine (Bio-Rad). All genes were normalized to 
a hypoxanthine guanine phosphoribosyl transferase (Hprt) gene. Primers of these genes 
were designed in advance and ordered from Integrated DNA Technologies.  
2.3.11 Statistical analysis 
Comparisons of treatment group with control group were analyzed using two-tailed 
t-test. P values were calculated: * P < 0.05, ** P < 0.01. Both * and ** were consided as 
significant. 
2.4 Results 
2.4.1 S-ELNs strongly inhibited caspase-1 autocleavage and IL-1β secretion upon 
NLRP3 inflammasome activation 
Activation of the NLRP3 inflammasome leads to autocleavage of caspase-1 to 
produce the enzymatic active caspase-11 p10 and p20, which process pro-IL1β and pro-
IL18 to produce active IL-1β and IL18. Very often, caspase-1 autocleavage and IL-1β 
secretion are used as indicators of NLRP3 inflammasome activation (65). To screen the 
effects of different mushroom-derived ELNs on activation of the NLRP3 inflammasome, 
six mushrooms were chosen to extract ELNs: White beach mushroom (White buna 
shimeji), Brown beach mushroom (Brown buna shimeji), White common mushroom 
(White agaricus bisporus), Brown common mushroom (Brown agaricus bisporus), King 
mushroom (Pleurotus eryngii) and Shiitake mushroom (Lentinus edodes). Macrophages 
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were treated with mushroom-derived ELNs for 16 h. Mushroom-derived ELNs-primed 
macrophages were treated with LPS for 3 h and then were activated with FFA for 12 h. 
Caspase-1 autocleavage and IL-1β secretion were measured using western blot and ELISA, 
respectively. Among six mushroom-derived ELNs we tested, shiitake-derived ELNs (S-
ELNs) strongly inhibited both caspase-1 autocleavage and IL-1β secretion in a dose-
dependent manner (Figure 2F). In contrast with S-ELNs, white beach-derived ELNs and 
brown beach-derived ELNs had mild effects on caspase-1 autocleavage and IL-1β secretion 
(Figure 2A, 2B). Although king-derived ELNs mildly inhibited IL-1β secretion at high 
dose, it increased IL-1β at low dose and had no effects on caspase-1 autocleavage (Figure 
2C). White common-derived ELNs and brown common-derived ELNs suppressed IL-1β 
secretion, but they slightly increased caspase-1 production (Figure 2D, 2E). These results 
suggested that ELNs from shiitake mushroom were the only mushroom-derived ELNs that 
strongly inhibited caspase-1 autocleavage and IL-1β secretion upon NLRP3 inflammasome 
activation. Therefore, S-ELNs were chosen for further studies.  
2.4.2 Characterization of S-ELNs 
The size and morphology of S-ELNs were first characterized using Nanosight 
NS300 instrument and scanning electron microscope (SEM). Nanosight NS300 
measurement showed that the size of S-ELNs was distributed from 80 nm to 300 nm in 
diameter and most of them were accumulated at 115 nm in diameter (Figure 3A). 
Consistently, we further confirmed that S-ELNs had different sizes under SEM (Figure 
3B). S-ELNs were intact and round under SEM (Figure 3B), suggesting S-ELNs had 
similar shape and size as those of mammalian exosomes (35).  
32 
  
The cargos of S-ELNs were characterized by running RNA gel, protein gel, and 
TLC plate. Based on RNA electrophoresis result, the size of RNA in S-ELNs is less than 
50 nucleotides (nt) (Figure 3C). After adding RNase to RNA samples, the band was not 
detected (Figure 3C), indicating that the nucleic acids we extracted were RNAs. The 
proteins of S-ELNs were separated using SDS-PAGE gels. The results showed that three 
main bands were visualized after Coomassie Brilliant Blue staining. Their sizes were 
around 50 KDa, 30 KDa and 13 KDa, respectively (Figure 3D). The TLC plate results 
showed that lipids in S-ELNs were separated into three bands, and the majority of lipids in 
S-ELNs was accumulated on the top of the TLC plate (Figure 3E). These results 
demonstrated that the ELNs we isolated from shiitake mushroom were nanoparticles that 
contain cargos including RNAs, proteins, and lipids.  
2.4.3 S-ELNs were taken up by macrophages 
To assess whether S-ELNs were taken up by macrophages, we treated macrophages 
with either RNA-labeled S-ELNs or lipid-labeled S-ELNs at different doses. The results 
showed that the fluorescence of both RNA-labeled S-ELNs and lipid-labeled S-ELNs were 
detected in macrophages and fluorescence intensity was increased with dose of S-ELNs 
(Figure 4A, 4B), suggesting that S-ELNs, including the cargos inside of S-ELNs, were 
taken up by macrophages and the uptake was increased in a dose-dependent manner.  
2.4.4 S-ELNs suppressed the NLRP3 inflammasome activated by a range of stimuli 
Besides FFA, the NLRP3 inflammasome can be activated by other stimuli, 
including alum, nigericin and ATP (70,216,217). We further tested whether S-ELNs had 
effects on the NLRP3 inflammasome activated by alum, nigericin or ATP. Macrophages 
were treated with S-ELNs for 16 h. S-ELNs-primed macrophages were treated with LPS 
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for 3 h and then were activated with nigericin or ATP for 30 minutes, or alum for 5 h. 
Caspase-1 autocleavage and IL-1β secretion were measured using western blot and ELISA, 
respectively. Results showed that S-ELNs significantly suppressed caspase-1 autocleavage 
and IL-1β secretion when the NLRP3 inflammasome is activated by alum, nigericin and 
ATP (Figure 5A, 5B, 5C). Taken together, S-ELNs had broadly inhibitory effects on the 
NLRP3 inflammasome activated by different stimuli. 
2.4.5 S-ELNs blocked ASC speck formation 
ASC subunit is a key component involved in the assembly of NLRP3 
inflammasome and ASC contains CARD domain which is responsible for recruiting 
caspase-1 (61).  After stimulation, ASC is recruited by NLRP3 and subsequently form 
specks in the perinuclear area of the cell. Therefore, ASC specks could be used as an 
indicator of inflammasome assembly (62,63). To determine the effects of S-ELNs on 
inflammasome assembly, we assessed ASC speck formation with or without S-ELNs 
treatment in macrophages. ASC specks were formed when NLRP3 inflammasome was 
activated by FFA (Figure 6A, 6B). However, the number of ASC specks decreased 
significantly when macrophages were pre-incubated with S-ELNs (Figure 6A, 6B). This 
result indicated that S-ELN inhibited assembly of the NLRP3 inflammasome. 
2.4.6 S-ELNs decreased both protein and mRNA levels of the Il1b gene and 
decreased transcription levels of some inflammasome subunits 
Activation of the NLRP3 inflammasome requires two signals: the first signal 
stimulates transcription of the Nlrp3 and I1b genes; the second signal activates the 
assembly of NLRP3 inflammasome subunits including NLRP3, ASC and caspase-1, 
leading to the caspase-1 autocleavage and generation of mature IL-1β (61). Here, we 
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assessed the effects of S-ELNs on both protein and mRNA levels of the Il1b, Nlrp3, Pycard 
(Asc), and caspase-1 genes. After 16 h incubation with S-ELNs at different concentrations, 
macrophages were treated with LPS plus FFA to activate the NLRP3 inflammasome. We 
first measured the protein levels of NLRP3 inflammasome subunits using western blot. As 
shown in Figure 7A, S-ELN treatment significantly suppressed the protein levels of pro-
IL1β, but had marginal impact on protein levels of inflammasome subunits NLRP3, 
caspase-1, ASC or inflammasome mediator NIMA-related kinases 7 (Nek7) (218). We 
further tested whether S-ELNs have any inhibitory effect on mRNA levels of the Nlrp3, 
Pycard, caspase1, and Il1b genes after NLRP3 inflammasome was activated using LPS 
plus FFA. The qPCR results showed that S-ELNs suppressed transcription of the Il1b, 
caspase1 and Nlrp3 genes (Figure 7B, 7D, and 7E). S-ELNs treatment slightly decreased 
expression of the Pycard gene, but the effects were not statistically significant (Figure 7C). 
When the NLRP3 inflammasome was activated using LPS plus ATP, S-ELNs dramatically 
inhibited the protein level of pro-IL1β, but had no impact on protein levels of 
inflammasome subunits or mediator (Figure 8A). At the transcription level, S-ELNs 
strongly inhibited transcription of the Il1b, Pycard and caspase1 genes (Figure 8C, 8D, 
8E), but did not affect expression of the Nlrp3 gene (Figure 8B). Collectively, these results 
indicated that S-ELNs decreased both protein and mRNA levels of the Il1b gene and 
decreased transcription levels of some inflammasome subunits.  
2.4.7 Lipids in S-ELNs were identified as active agents that inhibit activation of the 
NLRP3 inflammasome 
To identify which category of biomolecules in S-ELNs has biological activity on 
inhibiting activation of the NLRP3 inflammasome, S-ELNs were subjected to different 
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treatment. S-ELNs were heated at 95 C for 10 min to denature proteins. RNAs in S-ELNs 
were depleted by bath sonication plus RNase treatment. Bath sonication disrupts membrane 
of ELNs and subsequently RNase can reach RNAs in the vesicles to catalyze the 
degradation of RNAs (156,219,220). To study the functional significance of lipids in S-
ELNs, the total lipids of S-ELNs were extracted, dried, and assembled into liposomes. 
Macrophages were treated with protein-denatured S-ELNs, RNA-depleted S-ELNs and 
liposomes prepared from S-ELN lipids for 16 h, respectively. Afterwards, LPS plus FFA 
were used to activate the NLRP3 inflammasome in macrophages. Protein-denatured S-
ELNs still had inhibitory effects on caspase-1 autocleavage and IL-1β secretion (Figure 
9A), indicating proteins in S-ELNs are not the active cargos that inhibit activation of the 
NLRP3 inflammasome. The inhibition of caspase-1 autocleavage and IL-1β secretion was 
not dramatically affected after removal of most RNAs in S-ELNs (Figure 9B), which 
suggested that RNAs in S-ELNs are not necessary for the inhibition of NLRP3 
inflammasome activation. The inhibitory effect of S-ELN derived liposomes was as strong 
as that of intact S-ELNs on caspase-1 autocleavage and IL-1β secretion (Figure 10). These 
results suggested that the active biomolecules in S-ELNs with anti-inflammasome 
functions were lipids rather than proteins and RNAs.  
2.5 Discussion 
In this study, we isolated and characterized ELNs from shiitake mushroom. We 
showed that S-ELNs are nanoparticles that contain cargos including RNAs, proteins, and 
lipids for the first time. Thus, S-ELNs had similar size and content as the mammalian 
exosomes (35). S-ELNs were taken up by macrophages in a dose-dependent manner. 
Importantly, we demonstrated the inhibitory effects of S-ELNs on caspase-1 autocleavage 
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and IL-1β secretion when NLRP3 inflammasome was activated by FFA. S-ELNs also 
inhibited the NLRP3 inflammasome activated by a range of stimuli, including alum, 
nigericin and ATP. S-ELNs blocked assembly of the NLRP3 inflammasome. In addition, 
S-ELNs inhibited the protein and mRNA levels of the Il1b gene. Furthermore, we identified 
lipids in S-ELNs as the activate cargos that inhibit caspase-1 autocleavage and IL-1β 
secretion. Collectively, our results showed that S-ELNs strongly inhibited the NLRP3 
inflammasome activation. 
Mushrooms have been demonstrated to have immune-modulatory properties to go 
against various diseases including diabetes, cancer, chronic hepatitis and arteriosclerosis 
(221). The effects of mushrooms or their extracts on the NLRP3 inflammasome activation 
have also been studied. Some mushrooms, such as almond mushroom (Agaricus blazei 
Murill), Turkey tail (Trametes Versicolor) and lentinan from shiitake mushroom (Lentinus 
edodes), have been reported to activate the NLRP3 inflammasome, and therefore lead to 
inflammatory cell death (222-224). However, some of other mushrooms like golden oyster 
mushroom (Pleurotus citrinopileatus) inhibited NLRP3 inflammasome activation (225). 
Thus, we decided to investigate the role of mushroom-derived ELNs in the NLRP3 
inflammasome activation. We evaluated the effects of six mushroom-derived ELNs on the 
NLRP3 inflammasome activation. Interestingly, different kinds of mushroom-derived 
ELNs have different effects on the NLRP3 inflammasome activation. Among the 
mushroom-derived ELNs we tested, S-ELNs were the only one that strongly inhibited 
caspase-1 autocleavage and IL-1β secretion (Figure 2F). Unlike S-ELNs, White beach-
derived ELNs, brown beach-derived ELNs and king-derived ELNs did not show significant 
effects on both caspase-1 autocleavage and IL-1β secretion (Figure 2A, 2B, 2C). We 
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reasoned that these three mushroom-derived ELNs might lack some specific biomolecules 
that only present in S-ELNs. Although both white common-derived ELNs and brown 
common-derived ELNs significantly inhibited IL-1β secretion, they had no effects on 
caspase-1 autocleavage (Figure 2D, 2E).  
S-ELNs have similar shape and size (Figure 3A, 3B) as those of other dietary ELNs 
(34). RNAs, proteins, and lipids in S-ELNs were extracted and characterized in detail 
(Figure 3C, 3D, 3E). Thus, we considered S-ELNs as exosome-like nanoparticles (ELNs) 
that contain RNAs, protein, and lipids. Furthermore, we confirmed that macrophages were 
able to take up RNA-labeled and lipid-labeled S-ELNs (Figure 4A, 4B). However, the 
mechanism of this uptake is unknown. It has been suggested that exosomes are taken up 
by cells through endocytosis and micropinocytosis (226). In the future study, we will 
explore the mechanism underlying how macrophages take up S-ELNs.  
The NLRP3 inflammasome is activated by a broad range of stimuli including FFAs, 
alum, nigericin and ATP (70,216,217). Here, we demonstrated the inhibitory effects of S-
ELNs on the NLRP3 inflammasome activated by FFA, alum, nigericin and ATP (Figure 
2F, 5A, 5B, 5C), indicating S-ELNs have a broad inhibitory effect on the NLRP3 
inflammasome activation. Importantly, S-ELNs seem to have multiple targets that 
converge on the NLRP3 inflammasome and thus synergistically or additively suppress 
NLRP3 inflammasome activity. First, S-ELNs inhibited assembly of the inflammasome 
(Figure 6A, 6B), Second, S-ELNs inhibited both protein and mRNA levels of the Il1b gene 
when macrophages were activated by LPS plus FFA or LPS plus ATP (Figure 7A, 7E, 8A, 
8E), suggesting the potential role of S-ELNs in attenuating NF-B pathway. Finally, S-
ELNs inhibited expression of some inflammasome subunits (Figure 7B, 7D, 8C, 8D).  
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Lentinan extracted from shiitake mushroom has been shown to inhibit AIM2 
inflammasome activation, but not NLRP3 inflammasome (227). In the future study, we 
will evaluate the effects of S-ELNs on activation of other inflammasomes. Together, these 
results provide a basis to further study the mechanisms underlying how S-ELNs inhibit 
NLRP3 inflammasome activation.  
Exosomes and dietary ELNs participate in the intercellular communication or even 
interspecies communication by delivering their cargoes to target cells (34). Evidence has 
demonstrated that the RNA cargos in exosomes or ELNs have biological activity (154). 
We found that the inhibitory effect of lipids from S-ELNs was as strong as that of intact S-
ELNs (Figure 10). Further identification of specific lipid components in S-ELNs that 
inhibit NLRP3 inflammasome activation is needed. In addition, further study is warranted 
to demonstrate the inhibitory effects of lipids in S-ELNs on NLRP3 inflammasome 









CHAPTER 3. DISCUSSION, LIMITATION, AND FUTURE STUDIES 
3.1 Discussion 
The NLRP3 inflammasome is a multiprotein complex containing NLRP3, ASC and 
capase-1 (65). It is activated by a variety of exogenous PAMPs and endogenous DAMPs 
and therefore plays an important role in immune system (65). However, dysregulated or 
excessive activation of the NLRP3 inflammasome contributes to the pathogenesis of many 
diseases including Alzheimer’s disease, type 2 diabetes, and gout (213-215). Accumulating 
evidence has demonstrated that inhibition of the NLRP3 inflammasome has high 
therapeutic potential for treatment of NLRP3 inflammasome-related diseases (213,214). 
Exosomes are bilayer membrane-enclosed nanoparticles containing RNAs, proteins and 
lipids (23). They play an important role in intercellular communication (34,106). Besides 
endogenous exosomes, exosomes or exosome-like nanoparticles (ELNs) obtained from 
dietary sources have been identified and characterized (34,228), and their therapeutic 
potential for treatment of diseases has also been studied (30). A few studies have suggested 
that RNAs in bovine milk exosomes affect the biological activities of target cells (220,229), 
but the functional significance of cargos from edible plant-derived ELNs in consumers are 
still controversial. In addition, only a few edible plant-derived ELNs have been studied and 
many more dietary ELNs  await further investigation. 
3.1.1 Inhibition of the NLRP3 inflammasome 
Inflammation protects body against exogenous pathogens and this function is 
beneficial to human health (230). However, aberrant inflammation contributes to the 
pathogenesis of diseases (230). Dysregulated or excessive activation of the NLRP3 
inflammasome leads to continuous release of IL-1β, which is associated with a variety of 
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chronic inflammatory diseases, including diabetes and atherosclerosis (11,231). IL-1β 
inhibitors have been utilized in treating these diseases in clinical trials (232), but these 
inhibitors showed modest effects possibly because they only inhibit one downstream event 
of the NLRP3 inflammasome (61). Some molecules have been discovered to inhibit 
NLRP3 inflammasome activation in vivo or in vitro. For example, the neurotransmitter 
dopamine inhibited NLRP3 inflammasome activation via dopamine D1 receptor in 
macrophages. This study provides a promising approach for preventing neuroinflammation 
(233). Similarly, nitric oxide has been demonstrated to inhibit NLRP3 inflammasome 
activation through stabilizing mitochondria (234,235). A small-molecule chemical called 
MCC950 inhibited NLRP3 inflammation activation and protected mice from autoimmune 
diseases and cognitive decline (18,236). BAY11-7082 protected mice from spinal cord 
injury-induced lung injury by inhibiting NLRP3 inflammasome activation (237). Other 
pharmaceutical NLRP3 inhibitors including IFM-514, IFM-632 and CRID3 have also been 
investigated for their efficacy in the retinal pigment epithelium cells, thereby providing 
promising agents for treatment of atrophic age-related macular degeneration (238). Aspirin 
has been widely used in clinical treatment due to its anti-inflammatory effect. It has been 
demonstrated to have inhibitory effects on activation of the NLRP3 inflammasome via 
suppression of ROS (239).  
Besides endogenous molecules and pharmacological molecules, some natural 
molecules from herbs or foods have also been reported to have inhibitory effects on NLRP3 
inflammasome activation. Kaempferol found in herbs has been identified as a potential 
inhibitor that suppresses NLRP3 inflammasome activation via ubiquitin-autolysosome 
pathway (240). As a result, kaempferol treatment reduced neuroinflammation and 
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protected mice against neurodegeneration in Parkinson’s disease (240). Another food-
borne molecule naringenin also inhibited NLRP3 inflammasome activation and therefore 
protected against LPS-induced dopamine neurotoxicity in Parkinson’s disease (241). 
Laurus nobilis leaf extract suppressed NLRP3 inflammasome activation in macrophages 
possibly through 1,8-cineole, a major component of this leaf extract (242). When L. nobilis 
leaf extract were administered to mice, they reduced  expression of proinflammatory 
cytokine genes in an acute lung injury murine model (242). Despite these interesting 
findings, the efficacy and safety of these molecules for long-term usage in chronic diseases 
such as diabetes have not been evaluated. Therefore, there is a need to expand the pool of 
inflammasome inhibitors. Mushrooms have potential in inhibition of NLRP3 
inflammasome activation (225), but more direct evidence is needed to support such 
functions. Our results demonstrate for the first time that S-ELNs strongly inhibit NLRP3 
inflammasome activation in macrophages (Figure 2F). Thus, S-ELNs represent a new 
promising agent that blocks NLRP3 inflammasome activation. 
3.1.2 Therapeutic potential of dietary exosome-like nanoparticles (ELNs) 
Dietary ELNs have been reported as promising therapeutic approaches for 
treatment of diseases. Grape-derived ELNs were taken up by intestinal macrophages and 
intestinal stem cells, indicating a possible role of dietary ELNs in mediating interspecies 
communication (34). Grape-derived ELNs promoted the growth of Lgr5+ intestinal stem 
cells, therefore protecting mice against DSS-induced colitis (30). Ginger-derived ELNs 
also show anti-inflammatory property, because ginger-derived ELNs ameliorated disease 
symptoms in DDS-induced colitis mouse models (243). In addition, ginger-derived ELNs 
mediated nuclear factor erythroid 2-related factor (Nrf2) activation in liver cells, and 
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therefore protected mice against alcohol-induced liver injury (244). Unlike grape-derived 
ELNs, ginger-derived ELNs were taken up by intestinal epithelial cells (243). Bovine milk 
exosomes (BMEs) regulated gene expression and the levels of amino acids in skeletal 
muscles in mice (227). In addition, BMEs affected the cognitive performance and gut 
microbiome in mice (38,245). BMEs enhanced mucin production by increasing goblet cell 
activity (246). In addition, BMEs promoted protein synthesis by inducing expression of 
GRP94, a intraluminal endoplasmic reticulum chaperones involved in protein folding (246). 
As a result, BME treatment protected mice against necrotizing enterocolitis (NEC)-induced 
intestinal injury (246). Recently, a study from our laboratory suggested that ginger-derived 
ELNs had strong inhibitory effect on NLRP3 inflammasome activation (247). Together, 
dietary ELNs could regulate gene expression and activate functions of certain molecules at 
the molecular level (219,246) and promote cell proliferation at the cellular level (30,246). 
More importantly, dietary ELNs could protect mice against DSS-induced colitis, alcohol-
induced liver injury and NEC-induced intestinal injury at the pathophysiological level 
(30,244,246). 
3.1.3 Biological activities of cargos in dietary ELNs 
ELNs participate in the intercellular or interspecies communications by carrying 
RNAs, proteins and lipids (34,106). RNA cargos in BMEs regulated gene expression in 
target cells (220,229). The glycoproteins on the surface of BMEs play an important role in 
the uptake process in human and rat intestinal cells (151). MicroRNAs in BMEs are mainly 
distributed in intestinal mucosa, spleen, liver, heart and brain (155). This distribution 
pattern is distinctive from intact BMEs (155). In our study, we confirmed S-ELNs as 
exosome-like nanoparticles (ELNs) containing RNAs, proteins and lipids (Figure 3A-E). 
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we also discovered that S-ELNs, including the cargos inside of S-ELNs, were taken up by 
macrophages in a dose-dependent manner (Figure 4A, 4B). However, whether 
glycoproteins of S-ELNs play a critical role in the uptake process has not been studied. 
MicroRNAs in ginger-derived ELNs regulated the functions and motility of gut microbiota 
in the mice (248), while lipids in grape-derived ELNs  promoted proliferation of intestinal 
stem cells and liposome-like nanoparticles assembled from lipids of grape-derived ELNs 
play a crucial role in targeting intestinal stem cells (30). In addition, lipids from grapefruit-
derived ELNs have been utilized as a vector to deliver therapeutic agents for cancer 
treatment, because these lipids do not cause cytotoxicity and inflammatory response (149). 
Recently, lipids in ginger-derived ELNs have been demonstrated as active biomolecules 
that inhibit NLRP3 inflammasome activation (247). Similarly, lipids in S-ELNs have also 
been identified as bioactive agents that inhibit NLRP3 inflammasome activation in 
macrophages (Figure 10A). 
3.2 Limitation and future studies   
Here, we list four limitations in the current study and how we plan to address them 
in the future studies. Firstly, although we demonstrated the inhibitory effects of S-ELNs 
on NLRP3 inflammasome activated by a range of stimuli in macrophages, the mechanism 
underlying how S-ELNs inhibit NLRP3 inflammasome activation has not been studied. 
We mentioned three upstream events involved in NLRP3 inflammasome activation in the 
chapter 1: intracellular K+ efflux, reactive oxygen species (ROS) production, and 
lysosomal destabilization and rupture. We will assess intracellular KCl, the production of 
ROS and lysosomal dysfunction to demonstrate how S-ELNs inhibited NLRP3 
inflammasome activation at the cellular level. Secondly, we identified lipids as the active 
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agents that inhibit NLRP3 inflammasome activation. S-ELNs contain many different kinds 
of lipids (Figure 3E). The specific lipid that is responsible for anti-inflammasome functions 
has not been identified. To address this question, we plan to perform lipidomics analysis 
of lipids in S-ELNs. Among six mushroom-derived ELNs we tested, five mushroom-
derived ELNs have no effects on caspase-1 autocleavage or IL-1β secretion (Figure 2A, 
2B, 2C, 2D, 2E). We plant to choose one of these five inactive mushroom-derived ELNs 
as a negative control. The lipidomes of active S-ELNs and inactive mushroom-derived 
ELNs will be compared. The lipids specifically enriched in S-ELNs could be the potential 
candidates, which will be tested individually for their effects on NLRP3 inflammasome 
activation. Thirdly, we found that macrophages take up S-ELNs. Whether S-ELNs can be 
taken up by intestinal cells and how S-ELNs are distributed in mice have not been 
determined. Uptake, delivery and distribution of S-ELNs will be investigated in the future. 
Finally, we confirmed the inhibitory effects of S-ELNs on NLRP3 inflammasome 
activation in vitro, but the effects of S-ELNs on NLRP3 inflammasome activation in vivo 
have not been evaluated. We will determine whether oral administration or intravenous 
injection of S-ELNs could protect mice from NLRP3 inflammasome-related diseases. If S-
ELNs reduce inflammation and NLRP3 inflammasome activity in mice, we will further 
use Nlrp3-/- mice to confirm that anti-inflammatory functions of S-ELNs are mediated 











Figure 1. Activation of the NLRP3 inflammasome. Activation of the NLRP3 inflammasome requires two 
signals. Signal 1, such as LPS and TNFα, induces expression of the Nlrp3 and Il1b genes through toll-like 
receptor (TLR)/nuclear factor (NF)-κB pathway; Signal 2, such as ATP, FFAs and crystals, triggers 
assembly of the NLRP3 inflammasome. Activation of the NLRP3 inflammasome causes autocleavage of 
caspase-1 to produce the active caspase-1, which cleaves pro-IL-1β and pro-IL18 into active IL-1β and IL-











Figure 2. S-ELNs strongly inhibited caspase-1 autocleavage and IL-1β secretion upon NLRP3 
inflammasome activation. A-F. Macrophages were treated with mushroom-derived ELNs for 16 h and 
then treated with LPS for 3 h, and finally activated with FFA for 12 h. Caspase-1 autocleavage and IL-1β 
were measured using western blot and ELISA, respectively. Tubulin is used as a control to show equivalent 
loading. P values were calculated: * P < 0.05; ** P < 0.01. Treatment groups (mushroom-derived 
ELNs+LPS+FFA, white bars) were compared with the control group (LPS+FFA, black bar). A. White beach 
mushroom (White buna shimeji). B. Brown beach mushroom (Brown buna shimeji). C. King mushroom 
(Pleurotus eryngii). D. White common mushroom (White agaricus bisporus). E. Brown common mushroom 








Figure 3. Characterization of S-ELNs 
A. Size distribution and vesicle concentration of S-ELNs. B. scanning electron microscope images of S-
ELNs. C. RNAs of S-ELNs with or without RNase treatment were separated in the 2% agarose gel. D. 
Proteins extracted from S-ELNs were separated on the SDS-PAGE gel and stained using Coomassie 














Figure 4. S-ELNs were taken up by macrophages 
A.B. Macrophages were incubated with RNA-labeled or lipid-labeled S-ELNs at different doses for 16 h. 
The fluorescence was detected by confocal microscopy. A. Lipid-labeled S-ELNs were taken up by 













Figure 5. S-ELNs suppressed NLRP3 inflammasome activated by a range of stimuli  
A. S-ELNs suppressed alum-induced NLRP3 inflammasome activation. S-ELNs-primed BMDMs were 
treated with LPS for 3 h, and then activated with Alum for 5h. B. S-ELNs suppressed nigericin-induced 
NLRP3 inflammasome activation. S-ELNs-primed BMDMs were treated with LPS for 3 h, and then activated 
with nigericin for 30 minutes. C. S-ELNs suppressed ATP-induced NLRP3 inflammasome activation. S-
ELNs-primed BMDMs were treated with LPS for 3 h, and then activated with ATP for 30 minutes. Tubulin 
is used as a control to show equivalent loading. * P < 0.05; ** P < 0.01. Treatment group (S-











Figure 6. S-ELNs blocked ASC speck formation 
A. Immunofluorescence of ASC speck formation in macrophages stimulated with LPS+FFAs with or without 
S-ELNs incubation. Caspase-1 inhibitor VX765 (10 µM) were added 30 min before FFAs was incubated 
with cells. Yellow arrows indicate ASC specks. Anti-ASC rabbit antibody was used as primary antibody (1st 
Ab) and Alexa Fluor 594 anti-rabbit antibody was used as secondary antibody (2nd Ab).  B. Percentage of 
ASC speck positive cells. * P < 0.05; ** P < 0.01. Treatment group (LPS+FFA+S-ELNs, white bar) was 









Figure 7. S-ELNs suppressed pro-IL-1 protein level and expression of the Il1b, Nlrp3, and caspase1 
genes when inflammasome is activated using LPS+FFA. 
A-E. Macrophages were treated with S-ELNs for 16 h, and then treated with LPS for 3 h, and finally activated 
with FFAs for 12h. Cells were collected for analysis of protein and mRNA levels, respectively. A. S-ELN 
treatment significantly suppressed the protein level of pro-IL-1β. B. S-ELNs significantly suppressed 
transcription of the Nlrp3 gene. C. S-ELNs slightly decreased expression of the Pycard gene. D. S-ELNs 
significantly suppressed transcription of the caspase1 gene. E. S-ELNs significantly suppressed 
transcription of the Il1b gene. * P < 0.05; ** P < 0.01. Treatment groups (S-ELNs+LPS+FFA, white bars) 









Figure 8. S-ELNs suppressed pro-IL-1 protein level and expression of the Il1b, Pycard, and 
caspase1 genes when inflammasome is activated using LPS+ATP. 
A-E. Macrophages were treated with S-ELNs for 16 h, and then treated with LPS for 3 h, and finally activated 
with ATP for 0.5 h. Cells were collected for analysis of protein and mRNA levels, respectively. A. S-ELNs 
dramatically inhibited the protein level of pro-IL-1 β. B. S-ELNs had no impact on expression of the Nlrp3 
gene. C. S-ELNs significantly inhibited transcription of the Pycard gene. D. S-ELNs significantly inhibited 
transcription of the caspase1 gene. E. S-ELNs significantly inhibited transcription of the Il1b gene. * P < 
0.05; ** P < 0.01. Treatment groups (S-ELNs+LPS+ATP, white bars) were compared with the control group 










Figure 9. Protein and RNAs in S-ELNs were not the major bioactive agents that inhibit NLRP3 
inflammasome activation. A.B. Macrophages were incubated with S-ELNs that were subjected to 
different treatments for 16 h, and then stimulated with LPS+FFA. A. Protein-denatured S-ELNs still had 
inhibitory effects on caspase-1 autocleavage and IL-1β secretion. Proteins in S-ELNs were denatured 
by heating at 95 C for 10 min. Macrophages were treated with 61010/ml of regular S-ELNs (reg) or 
protein-denatured S-ELNs (heated). B. Removal of the majority of RNAs did not affect the inhibitory 
effects of S-ELNs on caspase-1 autocleavage and IL-1β secretion. RNAs in S-ELNs were removed 
through bath sonication plus RNase (S/R) treatment. Macrophages were treated with 61010/ml of 
regular S-ELNs (reg) or RNA-depleted S-ELNs (S/R-treated). Tubulin is used as a control to show 
equivalent loading. * P < 0.05; ** P < 0.01. Treatment groups (S-ELNs or protein-denatured S-ELNs or 














Figure 10. Lipids in S-ELNs were identified as bioactive agents that inhibit NLRP3 inflammasome 
activation. Lipids from S-ELNs strongly inhibited caspase-1 autocleavage and IL-1β secretion. Lipids 
were extracted from S-ELNs and then re-assembled into liposomes. Macrophages were treated with 
regular S-ELNs (reg) or liposomes. Tubulin is used as a control to show equivalent loading. * P < 0.05; 
** P < 0.01. Treatment groups (S-ELNs or liposomes+LPS+FFA, white bars) were compared with the 







ASC— Apoptotic speck protein containing a caspase recruitment domain 
ATP—Adenosine triphosphate 
BMDM-Bone marrow-derived macrophages 
BMEs—Bovine milk exosomes 
CARD—Caspase recruitment domain 
DAMPs—Damage-associated molecular patterns 
DAPI—4′,6-diamidino-2-phenylindole 
DHA—Docosahexaenoic acid 




FBS—Fetal bovine serum 
FFA—Free fatty acid sodium palmitate 
FFAs—Free fatty acids 
HEPES—4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HFD—High fat diet 
Hprt—hypoxanthine guanine phosphoribosyl transferase 






MAPKs—mitogen-activated protein kinases 
MHC—Major histocompatibility complex 
NaCl—Sodium chloride 
NEC—Necrotizing enterocolitis 
NEK—NIMA-related kinases 7 
NF-κB—Nuclear factor kappa B 
NK-T cells—Natural killer T cells 
NLRP3—NOD-like receptor family, pyrin domain containing 3  
NLRs—NOD-like receptors 
NOD/NACHT—Nucleotide-binding-and-oligomerization 
Nrf2—nuclear factor erythroid 2-related factor 
nt—Nucleotide 
PAMPs—Pathogen-associated molecular patterns 
PA—Palmitate 
PBS—phosphate buffered saline 
PI3K—phosphatidylinositol 3-kinase 
Pro-IL-1β—Pro-interleukin-1β 
PRRs— Pattern recognition receptors 
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PSPC—Purple sweet potato color 
PUFAs—polyunsaturated fatty acids 
PVDF—Polyvinylidene difluoride 
PYD—pyrin domain 
qPCR—Quantitative polymerase chain reaction 
ROS—Reactive oxygen species  
SDS-PAGE—sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SDS—Sodium dodecyl sulfate 
S-ELNs—shiitake-derived exosome-like nanoparticles 
SFAs—Saturated fatty acids 
STAT3—Signal transducer and activator of transcription 3 
TLC—thin-layer chromatography 
TLR 2/4—toll-like receptor 2/4 
TLRs—Toll-like receptors 
TNFα—Tumor necrosis factor-α 
UFAs—unsaturated fatty acids 



















1. Chen, G. Y., & Nuñez, G. (2010). Sterile inflammation: sensing and reacting to damage. 
Nature Reviews Immunology, 10(12), 826. 
2. Medzhitov, R. (2008). Origin and physiological roles of inflammation. Nature, 454(7203), 
428. 
3. Feghali, C. A., & Wright, T. M. (1997). Cytokines in acute and chronic inflammation. Front 
Biosci, 2(1), d12-d26. 
4. Spencer, W. G. (1936). Celsus de medicina. The American Journal of the Medical 
Sciences, 191(3), 424 
5. Celsus, A. C. (1935). De Medicina. Spencer WG, trans. vol. 3. 
6. Ryan, G. B., & Majno, G. (1977). Acute inflammation. A review. The American journal of 
pathology, 86(1), 183. 
7. Couzin-Frankel, J. (2010). Inflammation bares a dark side. 
8. Takeuchi, O., & Akira, S. (2010). Pattern recognition receptors and inflammation. Cell, 
140(6), 805820. 
9. Franchi, L., Muñoz-Planillo, R., & Núñez, G. (2012). Sensing and reacting to microbes 
through the inflammasomes. Nature immunology, 13(4), 325. 
10. Lamkanfi, M., & Dixit, V. M. (2012). Inflammasomes and their roles in health and disease. 
Annual review of cell and developmental biology, 28, 137-161. 
11. Strowig, T., Henao-Mejia, J., Elinav, E., & Flavell, R. (2012). Inflammasomes in health and 
disease. nature, 481(7381), 278. 
12. Wang, X., Feuerstein, G. Z., Gu, J. L., Lysko, P. G., & Yue, T. L. (1995). Interleukin-1β 
induces expression of adhesion molecules in human vascular smooth muscle cells and 
enhances adhesion of leukocytes to smooth muscle cells. Atherosclerosis, 115(1), 89-98. 
13. Bhaskar, V., Yin, J., Mirza, A. M., Phan, D., Vanegas, S., Issafras, H., ... & Kantak, S. S. 
(2011). Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in 
vitro and inhibit atherosclerotic plaque formation in Apolipoprotein E-deficient mice. 
Atherosclerosis, 216(2), 313-320. 
14. Boni-Schnetzler, M., Thorne, J., Parnaud, G., Marselli, L., Ehses, J. A., Kerr-Conte, J., ... 
& Donath, M. Y. (2008). Increased interleukin (IL)-1β messenger ribonucleic acid 
expression in β-cells of individuals with type 2 diabetes and regulation of IL-1β in human 
islets by glucose and autostimulation. The Journal of Clinical Endocrinology & Metabolism, 
93(10), 4065-4074. 
15. Cook, G. P., Savic, S., Wittmann, M., & McDermott, M. F. (2010). The NLRP3 
inflammasome, a target for therapy in diverse disease states. European journal of 
immunology, 40(3), 631-634. 
16. Vandanmagsar, B., Youm, Y. H., Ravussin, A., Galgani, J. E., Stadler, K., Mynatt, R. L., ... 
& Dixit, V. D. (2011). The NLRP3 inflammasome instigates obesity-induced inflammation 
and insulin resistance. Nature medicine, 17(2), 179. 
17. Youm, Y. H., Adijiang, A., Vandanmagsar, B., Burk, D., Ravussin, A., & Dixit, V. D. (2011). 
Elimination of the NLRP3-ASC inflammasome protects against chronic obesity-induced 
pancreatic damage. Endocrinology, 152(11), 4039-4045. 
18. Coll, R. C., Robertson, A. A., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., 
... & Croker, D. E. (2015). A small-molecule inhibitor of the NLRP3 inflammasome for the 
treatment of inflammatory diseases. Nature medicine, 21(3), 248. 
19. Lee, Y., El Andaloussi, S., & Wood, M. J. (2012). Exosomes and microvesicles: 
extracellular vesicles for genetic information transfer and gene therapy. Human molecular 
genetics, 21(R1), R125-R134. 
20. Raposo, G., & Stoorvogel, W. (2013). Extracellular vesicles: exosomes, microvesicles, and 
friends. J Cell Biol, 200(4), 373-383. 
58 
  
21. Akers, J. C., Gonda, D., Kim, R., Carter, B. S., & Chen, C. C. (2013). Biogenesis of 
extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic 
bodies. Journal of neuro-oncology, 113(1), 1-11. 
22. Shao, H., Im, H., Castro, C. M., Breakefield, X., Weissleder, R., & Lee, H. (2018). New 
technologies for analysis of extracellular vesicles. Chemical reviews, 118(4), 1917-1950. 
23. Ludwig, A. K., & Giebel, B. (2012). Exosomes: small vesicles participating in intercellular 
communication. The international journal of biochemistry & cell biology, 44(1), 11-15. 
24. Silva, A. M., Teixeira, J. H., Almeida, M. I., Gonçalves, R. M., Barbosa, M. A., & Santos, S. 
G. (2017). Extracellular vesicles: immunomodulatory messengers in the context of tissue 
repair/regeneration. European Journal of Pharmaceutical Sciences, 98, 86-95. 
25. Raposo, G., Nijman, H. W., Stoorvogel, W., Liejendekker, R., Harding, C. V., Melief, C. J., 
& Geuze, H. J. (1996). B lymphocytes secrete antigen-presenting vesicles. Journal of 
Experimental Medicine, 183(3), 1161-1172.  
26. Dinkins, M. B., Dasgupta, S., Wang, G., Zhu, G., & Bieberich, E. (2014). Exosome 
reduction in vivo is associated with lower amyloid plaque load in the 5XFAD mouse model 
of Alzheimer's disease. Neurobiology of aging, 35(8), 1792-1800. 
27. Singh, R., Pochampally, R., Watabe, K., Lu, Z., & Mo, Y. Y. (2014). Exosome-mediated 
transfer of miR-10b promotes cell invasion in breast cancer. Molecular cancer, 13(1), 256. 
28. An, Q., Hückelhoven, R., Kogel, K. H., & Van Bel, A. J. (2006). Multivesicular bodies 
participate in a cell wall‐associated defence response in barley leaves attacked by the 
pathogenic powdery mildew fungus. Cellular microbiology, 8(6), 1009-1019. 
29. Regente, M., Pinedo, M., Elizalde, M., & de la Canal, L. (2012). Apoplastic exosome-like 
vesicles: a new way of protein secretion in plants?. Plant signaling & behavior, 7(5), 544-
546. 
30. Ju, S., Mu, J., Dokland, T., Zhuang, X., Wang, Q., Jiang, H., ... & Roth, M. (2013). Grape 
exosome like nanoparticles induce intestinal stem cells and protect mice from DSS-induced 
colitis. Molecular Therapy, 21(7), 1345-1357. 
31. Cheruvanky, A., Zhou, H., Pisitkun, T., Kopp, J. B., Knepper, M. A., Yuen, P. S., & Star, R. 
A. (2007). Rapid isolation of urinary exosomal biomarkers using a nanomembrane 
ultrafiltration concentrator. American Journal of Physiology-Renal Physiology, 292(5), 
F1657-F1661. 
32. Nabhan, J. F., Hu, R., Oh, R. S., Cohen, S. N., & Lu, Q. (2012). Formation and release of 
arrestin domain-containing protein 1-mediated microvesicles (ARMMs) at plasma 
membrane by recruitment of TSG101 protein. Proceedings of the National Academy of 
Sciences, 109(11), 4146-4151. 
33. Arntz, O. J., Pieters, B. C., Oliveira, M. C., Broeren, M. G., Bennink, M. B., de Vries, M., ... 
& van de Loo, F. A. (2015). Oral administration of bovine milk derived extracellular vesicles 
attenuates arthritis in two mouse models. Molecular nutrition & food research, 59(9), 1701-
1712. 
34. Mu, J., Zhuang, X., Wang, Q., Jiang, H., Deng, Z. B., Wang, B., ... & Zhang, H. G. (2014). 
Interspecies communication between plant and mouse gut host cells through edible plant 
derived exosome‐like nanoparticles. Molecular nutrition & food research, 58(7), 1561-
1573. 
35. Sokolova, V., Ludwig, A. K., Hornung, S., Rotan, O., Horn, P. A., Epple, M., & Giebel, B. 
(2011). Characterisation of exosomes derived from human cells by nanoparticle tracking 
analysis and scanning electron microscopy. Colloids and Surfaces B: Biointerfaces, 87(1), 
146-150. 
36. Kusuma, R. J., Manca, S., Friemel, T., Sukreet, S., Nguyen, C., & Zempleni, J. (2016). 
Human vascular endothelial cells transport foreign exosomes from cow's milk by 
endocytosis. American Journal of Physiology-Cell Physiology, 310(10), C800-C807. 
59 
  
37. Sukreet, S., Zhang, H., Adamec, J., Cui, J., & Zempleni, J. (2016). Identification of 
glycoproteins on the surface of Cow’s milk exosomes that mediate the uptake of exosomes 
into human colon carcinoma Caco-2 Cells. The FASEB journal, 30(1_supplement), 125-1.  
38. Mutai, E., Zhou, F., & Zempleni, J. (2017). Depletion of dietary bovine milk exosomes 
impairs sensorimotor gating and spatial learning in C57BL/6 mice. The FASEB Journal, 
31(1_supplement), 150-4. 
39. Benmoussa, A., Lee, C. H. C., Laffont, B., Savard, P., Laugier, J., Boilard, E., ... & Provost, 
P. (2016). Commercial dairy cow milk microRNAs resist digestion under simulated 
gastrointestinal tract conditions. The Journal of nutrition, 146(11), 2206-2215.  
40. Manca, S., Giraud, D., & Zempleni, J. (2017). The bioavailability and distribution of bovine 
milk exosomes is distinct from that of their cargos in mice. The FASEB Journal, 
31(1_supplement), 148-2. 
41. Rathore, H., Prasad, S., & Sharma, S. (2017). Mushroom nutraceuticals for improved 
nutrition and better human health: a review. PharmaNutrition, 5(2), 35-46. 
42. Badalyan, S. (2012). Medicinal aspects of edible ectomycorrhizal mushrooms. In Edible 
Ectomycorrhizal Mushrooms (pp. 317-334). Springer, Berlin, Heidelberg. 
43. Elsayed, E. A., El Enshasy, H., Wadaan, M. A., & Aziz, R. (2014). Mushrooms: a potential 
natural source of anti-inflammatory compounds for medical applications. Mediators of 
inflammation, 2014. 
44. Taofiq, O., Martins, A., Barreiro, M. F., & Ferreira, I. C. (2016). Anti-inflammatory potential 
of mushroom extracts and isolated metabolites. Trends in Food Science & Technology, 50, 
193-210. 
45. Liu, K., Wang, J., Zhao, L., & Wang, Q. (2013). Anticancer, antioxidant and antibiotic 
activities of mushroom Ramaria flava. Food and chemical toxicology, 58, 375-380. 
46. Turkoglu, A., Duru, M. E., Mercan, N., Kivrak, I., & Gezer, K. (2007). Antioxidant and 
antimicrobial activities of Laetiporus sulphureus (Bull.) Murrill. Food Chemistry, 101(1), 
267-273. 
47. Ooi, V. E. C., & Liu, F. (1999). A review of pharmacological activities of mushroom 
polysaccharides. International Journal of Medicinal Mushrooms, 1(3). 
48. Zaidman, B. Z., Yassin, M., Mahajna, J., & Wasser, S. P. (2005). Medicinal mushroom 
modulators of molecular targets as cancer therapeutics. Applied Microbiology and 
Biotechnology, 67(4), 453-468. 
49. Jeong, S. C., Jeong, Y. T., Yang, B. K., Islam, R., Koyyalamudi, S. R., Pang, G., ... & Song, 
C. H. (2010). White button mushroom (Agaricus bisporus) lowers blood glucose and 
cholesterol levels in diabetic and hypercholesterolemic rats. Nutrition research, 30(1), 49-
56. 
50. Kim, S. H., Thomas, M. J., Wu, D., Carman, C. V., Ordovás, J. M., & Meydani, M. (2019). 
Edible Mushrooms Reduce Atherosclerosis in Ldlr−/− Mice Fed a High-Fat Diet. The 
Journal of nutrition. 
51. Adams, L. S., Chen, S., Phung, S., Wu, X., & Ki, L. (2008). White button mushroom 
(Agaricus bisporus) exhibits antiproliferative and proapoptotic properties and inhibits 
prostate tumor growth in athymic mice. Nutrition and cancer, 60(6), 744-756. 
52. Kim, H., Cho, K. M., Gerelchuluun, T., Lee, J. S., Chung, K. S., & Lee, C. K. (2007). Lectins 
isolated from mushroom Fomitella fraxinea enhance MHC-restricted exogenous antigen 
presentation. Immune Network, 7(4), 197-202. 
53. Bernardshaw, S., Johnson, E., & Hetland, G. (2005). An extract of the mushroom Agaricus 
blazei Murill administered orally protects against systemic Streptococcus pneumoniae 
infection in mice. Scandinavian Journal of Immunology, 62(4), 393-398. 
54. Karasawa, T., Kawashima, A., Usui-Kawanishi, F., Watanabe, S., Kimura, H., Kamata, R., 
... & Tomoda, H. (2018). Saturated fatty acids undergo intracellular crystallization and 
activate the NLRP3 inflammasome in macrophages. Arteriosclerosis, thrombosis, and 
vascular biology, 38(4), 744-756. 
60 
  
55. L'homme, L., Esser, N., Riva, L., Scheen, A., Paquot, N., Piette, J., & Legrand-Poels, S. 
(2013). Unsaturated fatty acids prevent activation of NLRP3 inflammasome in human 
monocytes/macrophages. Journal of lipid research, 54(11), 2998-3008. 
56. Yan, Y., Jiang, W., Spinetti, T., Tardivel, A., Castillo, R., Bourquin, C., ... & Zhou, R. (2013). 
Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of 
NLRP3 inflammasome activation. Immunity, 38(6), 1154-1163. 
57. Yang, H., Xiao, L., Yuan, Y., Luo, X., Jiang, M., Ni, J., & Wang, N. (2014). Procyanidin B2 
inhibits NLRP3 inflammasome activation in human vascular endothelial cells. Biochemical 
pharmacology, 92(4), 599-606.  
58. Sun, C., Fan, S., Wang, X., Lu, J., Zhang, Z., Wu, D., ... & Zheng, Y. (2015). Purple sweet 
potato color inhibits endothelial premature senescence by blocking the NLRP3 
inflammasome. The Journal of nutritional biochemistry, 26(10), 1029-1040.  
59. Proell, M., Riedl, S. J., Fritz, J. H., Rojas, A. M., & Schwarzenbacher, R. (2008). The Nod-
like receptor (NLR) family: a tale of similarities and differences. PloS one, 3(4), e2119. 
60. Ting, J. P. Y., Lovering, R. C., Alnemri, E. S., Bertin, J., Boss, J. M., Davis, B. K., ... & 
Hoffman, H. M. (2008). The NLR gene family: a standard nomenclature. Immunity, 28(3), 
285-287. 
61. Hernandez, J. C., Sirois, C. M., & Latz, E. (2011). Activation and regulation of the NLRP3 
inflammasome. In The inflammasomes (pp. 197-208). Springer, Basel. 
62. Bryan, N. B., Dorfleutner, A., Rojanasakul, Y., & Stehlik, C. (2009). Activation of 
inflammasomes requires intracellular redistribution of the apoptotic speck-like protein 
containing a caspase recruitment domain. The Journal of Immunology, 182(5), 3173-3182. 
63. Stutz, A., Horvath, G. L., Monks, B. G., & Latz, E. (2013). ASC speck formation as a readout 
for inflammasome activation. In The Inflammasome (pp. 91-101). Humana Press, Totowa, 
NJ. 
64. Schroder, K., Zhou, R., & Tschopp, J. (2010). The NLRP3 inflammasome: a sensor for 
metabolic danger?. Science, 327(5963), 296-300. 
65. Martinon, F. et al. (2002) The inflammasome: a molecular platform triggering activation of 
inflammatory caspases and processing of proIL-b. Mol. Cell 10, 417–426 3.  
66. Wang, L. et al. (2002) PYPAF7, a novel PYRIN-containing Apaf1- like protein that regulates 
activation of NF-k B and caspase-1- dependent cytokine processing. J. Biol. Chem. 277, 
29874– 29880. 
67. Bergsbaken, T., Fink, S. L., & Cookson, B. T. (2009). Pyroptosis: host cell death and 
inflammation. Nature Reviews Microbiology, 7(2), 99. 
68. Sutterwala, F. S., Haasken, S., & Cassel, S. L. (2014). Mechanism of NLRP3 
inflammasome activation. Annals of the New York Academy of Sciences, 1319(1), 82. 
69. He, Y., Hara, H., & Núñez, G. (2016). Mechanism and regulation of NLRP3 inflammasome 
activation. Trends in biochemical sciences, 41(12), 1012-1021. 
70. COUILLIN, I., GOMBAULT, A., & Baron, L. (2013). ATP release and purinergic signaling 
in NLRP3 inflammasome activation. Frontiers in immunology, 3, 414. 
71. Muñoz-Planillo, R., Kuffa, P., Martínez-Colón, G., Smith, B. L., Rajendiran, T. M., & Núñez, 
G. (2013). K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial 
toxins and particulate matter. Immunity, 38(6), 1142-1153. 
72. Perregaux, D., & Gabel, C. A. (1994). Interleukin-1 beta maturation and release in 
response to ATP and nigericin. Evidence that potassium depletion mediated by these 
agents is a necessary and common feature of their activity. Journal of Biological Chemistry, 
269(21), 15195-15203. 
73. Petrilli, V., Papin, S., Dostert, C., Mayor, A., Martinon, F., & Tschopp, J. (2007). Activation 
of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell 
death and differentiation, 14(9), 1583. 
61 
  
74. Pelegrin, P., & Surprenant, A. (2006). Pannexin‐1 mediates large pore formation and 
interleukin‐1β release by the ATP‐gated P2X7 receptor. The EMBO journal, 25(21), 5071-
5082. 
75. Groß, C. J., Mishra, R., Schneider, K. S., Médard, G., Wettmarshausen, J., Dittlein, D. C., 
... & Magnani, G. (2016). K+ efflux-independent NLRP3 inflammasome activation by small 
molecules targeting mitochondria. Immunity, 45(4), 761-773. 
76. Cruz, C. M., Rinna, A., Forman, H. J., Ventura, A. L., Persechini, P. M., & Ojcius, D. M. 
(2007). ATP activates a reactive oxygen species-dependent oxidative stress response and 
secretion of proinflammatory cytokines in macrophages. Journal of Biological Chemistry, 
282(5), 2871-2879. 
77. Dostert, C., Pétrilli, V., Van Bruggen, R., Steele, C., Mossman, B. T., & Tschopp, J. (2008). 
Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. 
Science, 320(5876), 674-677. 
78. Bae, Y. S., Oh, H., Rhee, S. G., & Do Yoo, Y. (2011). Regulation of reactive oxygen species 
generation in cell signaling. Molecules and cells, 32(6), 491-509. 
79. van Bruggen, R., Köker, M. Y., Jansen, M., van Houdt, M., Roos, D., Kuijpers, T. W., & van 
den Berg, T. K. (2010). Human NLRP3 inflammasome activation is Nox1-4 independent. 
Blood, 115(26), 5398-5400. 
80. Bauernfeind, F., Bartok, E., Rieger, A., Franchi, L., Núñez, G., & Hornung, V. (2011). 
Cutting edge: reactive oxygen species inhibitors block priming, but not activation, of the 
NLRP3 inflammasome. The Journal of Immunology, 187(2), 613-617. 
81. Harrison, R. M., & Yin, J. (2000). Particulate matter in the atmosphere: which particle 
properties are important for its effects on health?. Science of the total environment, 249(1-
3), 85-101. 
82. Hornung, V., Bauernfeind, F., Halle, A., Samstad, E. O., Kono, H., Rock, K. L., ... & Latz, 
E. (2008). Silica crystals and aluminum salts activate the NALP3 inflammasome through 
phagosomal destabilization. Nature immunology, 9(8), 847. 
83. Franchi L, Núñez G. The Nlrp3 inflammasome is critical for aluminium hydroxide‐mediated 
IL‐1β secretion but dispensable for adjuvant activity. European journal of immunology. 
2008 Aug;38(8):2085-9. 
84. Spranger, J., Kroke, A., Möhlig, M., Hoffmann, K., Bergmann, M. M., Ristow, M., ... & 
Pfeiffer, A. F. (2003). Inflammatory cytokines and the risk to develop type 2 diabetes: 
results of the prospective population-based European Prospective Investigation into 
Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes, 52(3), 812-817. 
85. Maedler, K., Dharmadhikari, G., Schumann, D. M., & Størling, J. (2009). Interleukin-1 beta 
targeted therapy for type 2 diabetes. Expert opinion on biological therapy, 9(9), 1177-1188. 
86. Maedler, K., Dharmadhikari, G., Schumann, D. M., & Størling, J. (2009). Interleukin-1 beta 
targeted therapy for type 2 diabetes. Expert opinion on biological therapy, 9(9), 1177-1188. 
87. Ehses, J. A., Perren, A., Eppler, E., Ribaux, P., Pospisilik, J. A., Maor-Cahn, R., ... & 
Fontana, A. (2007). Increased number of islet-associated macrophages in type 2 diabetes. 
Diabetes, 56(9), 2356-2370. 
88. Riddle, M. C. (2003). sulfonylureas differ in effects on ischemic preconditioning—is it time 
to retire glyburide?. 
89. Lamkanfi, M., Mueller, J. L., Vitari, A. C., Misaghi, S., Fedorova, A., Deshayes, K., ... & 
Dixit, V. M. (2009). Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. The Journal of 
cell biology, 187(1), 61-70. 
90. Ross, R. (1999). Atherosclerosis—an inflammatory disease. New England journal of 
medicine, 340(2), 115-126. 
91. Katz, S. S., Shipley, G. G., & Small, D. M. (1976). Physical chemistry of the lipids of human 
atherosclerotic lesions. Demonstration of a lesion intermediate between fatty streaks and 
advanced plaques. The Journal of clinical investigation, 58(1), 200-211. 
62 
  
92. Galea, J., Armstrong, J., Gadsdon, P., Holden, H., Francis, S. E., & Holt, C. M. (1996). 
Interleukin-1β in coronary arteries of patients with ischemic heart disease. Arteriosclerosis, 
thrombosis, and vascular biology, 16(8), 1000-1006. 
93. Kirii, H., Niwa, T., Yamada, Y., Wada, H., Saito, K., Iwakura, Y., ... & Seishima, M. (2003). 
Lack of interleukin-1β decreases the severity of atherosclerosis in ApoE-deficient mice. 
Arteriosclerosis, thrombosis, and vascular biology, 23(4), 656-660. 
94. Wang, R., Wang, Y., Mu, N., Lou, X., Li, W., Chen, Y., ... & Tan, H. (2017). Activation of 
NLRP3 inflammasomes contributes to hyperhomocysteinemia-aggravated inflammation 
and atherosclerosis in apoE-deficient mice. Laboratory Investigation, 97(8), 922. 
95. Rajamäki, K., Lappalainen, J., Öörni, K., Välimäki, E., Matikainen, S., Kovanen, P. T., & 
Eklund, K. K. (2010). Cholesterol crystals activate the NLRP3 inflammasome in human 
macrophages: a novel link between cholesterol metabolism and inflammation. PloS one, 
5(7), e11765. 
96. Petrasek, J., Bala, S., Csak, T., Lippai, D., Kodys, K., Menashy, V., ... & Szabo, G. (2012). 
IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in 
mice. The Journal of clinical investigation, 122(10), 3476-3489. 
97. Lebeaupin, C., Proics, E., De Bieville, C. H. D., Rousseau, D., Bonnafous, S., Patouraux, 
S., ... & Saint-Paul, M. C. (2015). ER stress induces NLRP3 inflammasome activation and 
hepatocyte death. Cell death & disease, 6(9), e1879. 
98. Wree, A., Eguchi, A., McGeough, M. D., Pena, C. A., Johnson, C. D., Canbay, A., ... & 
Feldstein, A. E. (2014). NLRP3 inflammasome activation results in hepatocyte pyroptosis, 
liver inflammation, and fibrosis in mice. Hepatology, 59(3), 898-910. 
99. Yang, G., Lee, H. E., & Lee, J. Y. (2016). A pharmacological inhibitor of NLRP3 
inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high 
fat diet. Scientific reports, 6, 24399. 
100. Caby, M. P., Lankar, D., Vincendeau-Scherrer, C., Raposo, G., & Bonnerot, C. 
(2005). Exosomal-like vesicles are present in human blood plasma. International 
immunology, 17(7), 879-887. 
101. Pisitkun, T., Shen, R. F., & Knepper, M. A. (2004). Identification and proteomic 
profiling of exosomes in human urine. Proceedings of the National Academy of Sciences, 
101(36), 13368-13373. 
102. Michael, A., Bajracharya, S. D., Yuen, P. S., Zhou, H., Star, R. A., Illei, G. G., & 
Alevizos, I. (2010). Exosomes from human saliva as a source of microRNA biomarkers. 
Oral diseases, 16(1), 34-38. 
103. Admyre, C., Johansson, S. M., Qazi, K. R., Filén, J. J., Lahesmaa, R., Norman, 
M., ... & Gabrielsson, S. (2007). Exosomes with immune modulatory features are present 
in human breast milk. The Journal of immunology, 179(3), 1969-1978.  
104. Cocucci, E., Racchetti, G., & Meldolesi, J. (2009). Shedding microvesicles: 
artefacts no more. Trends in cell biology, 19(2), 43-51. 
105. Szatanek, R., Baran, J., Siedlar, M., & Baj-Krzyworzeka, M. (2015). Isolation of 
extracellular vesicles: determining the correct approach. International journal of molecular 
medicine, 36(1), 11-17. 
106. Simons, M., & Raposo, G. (2009). Exosomes–vesicular carriers for intercellular 
communication. Current opinion in cell biology, 21(4), 575-581. 
107. Ratajczak, J., Miekus, K., Kucia, M., Zhang, J., Reca, R., Dvorak, P., & Ratajczak, 
M. Z. (2006). Embryonic stem cell-derived microvesicles reprogram hematopoietic 
progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia, 
20(5), 847. 
108. Choi, D. S., Park, J. O., Jang, S. C., Yoon, Y. J., Jung, J. W., Choi, D. Y., ... & Lee, 
K. H. (2011). Proteomic analysis of microvesicles derived from human colorectal cancer 
ascites. Proteomics, 11(13), 2745-2751. 
63 
  
109. Miguet, L., Pacaud, K., Felden, C., Hugel, B., Martinez, M. C., Freyssinet, J. M., ... 
& Mauvieux, L. (2006). Proteomic analysis of malignant lymphocyte membrane 
microparticles using double ionization coverage optimization. Proteomics, 6(1), 153-171. 
110. Melo, S. A., Luecke, L. B., Kahlert, C., Fernandez, A. F., Gammon, S. T., Kaye, J., 
... & Reissfelder, C. (2015). Glypican-1 identifies cancer exosomes and detects early 
pancreatic cancer. Nature, 523(7559), 177. 
111. Kowal, J., Arras, G., Colombo, M., Jouve, M., Morath, J. P., Primdal-Bengtson, B., 
... & Théry, C. (2016). Proteomic comparison defines novel markers to characterize 
heterogeneous populations of extracellular vesicle subtypes. Proceedings of the National 
Academy of Sciences, 113(8), E968-E977. 
112. Lunavat, T. R., Cheng, L., Kim, D. K., Bhadury, J., Jang, S. C., Lässer, C., ... & 
Hill, A. F. (2015). Small RNA deep sequencing discriminates subsets of extracellular 
vesicles released by melanoma cells–Evidence of unique microRNA cargos. RNA biology, 
12(8), 810-823. 
113. Huang, X., Yuan, T., Tschannen, M., Sun, Z., Jacob, H., Du, M., ... & Kohli, M. 
(2013). Characterization of human plasma-derived exosomal RNAs by deep sequencing. 
BMC genomics, 14(1), 319. 
114. Thind, A., & Wilson, C. (2016). Exosomal miRNAs as cancer biomarkers and 
therapeutic targets. Journal of extracellular vesicles, 5(1), 31292. 
115. Batagov, A. O., & Kurochkin, I. V. (2013). Exosomes secreted by human cells 
transport largely mRNA fragments that are enriched in the 3′-untranslated regions. Biology 
direct, 8(1), 12. 
116. Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., & Lötvall, J. O. 
(2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of 
genetic exchange between cells. Nature cell biology, 9(6), 654. 
117. Montecalvo, A., Larregina, A. T., Shufesky, W. J., Stolz, D. B., Sullivan, M. L., 
Karlsson, J. M., ... & Milosevic, J. (2012). Mechanism of transfer of functional microRNAs 
between mouse dendritic cells via exosomes. Blood, 119(3), 756-766. 
118. Wang, C., Zhang, C., Liu, L., Xi, A., Chen, B., Li, Y., & Du, J. (2017). Macrophage-
derived mir-155-containing exosomes suppress fibroblast proliferation and promote 
fibroblast inflammation during cardiac injury. Molecular Therapy, 25(1), 192-204. 
119. Lässer, C. (2012). Exosomal RNA as biomarkers and the therapeutic potential of 
exosome vectors. Expert opinion on biological therapy, 12(sup1), S189-S197. 
120. Hu, G., Drescher, K. M., & Chen, X. (2012). Exosomal miRNAs: biological 
properties and therapeutic potential. Frontiers in genetics, 3, 56. 
121. Huang, X., Yuan, T., Liang, M., Du, M., Xia, S., Dittmar, R., ... & Tan, W. (2015). 
Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate 
cancer. European urology, 67(1), 33-41. 
122. Laulagnier, K., Motta, C., Hamdi, S., Sébastien, R. O. Y., Fauvelle, F., Pageaux, 
J. F., ... & Record, M. (2004). Mast cell-and dendritic cell-derived exosomes display a 
specific lipid composition and an unusual membrane organization. Biochemical Journal, 
380(1), 161-171. 
123. Llorente, A., Skotland, T., Sylvänne, T., Kauhanen, D., Róg, T., Orłowski, A., ... & 
Sandvig, K. (2013). Molecular lipidomics of exosomes released by PC-3 prostate cancer 
cells. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids, 1831(7), 
1302-1309. 
124. Needham D, Nunn RS. Elastic deformation and failure of lipid bilayer membranes 
containing cholesterol. Biophysical journal. 1990 Oct 1;58(4):997-1009. 
125. Abi-Rizk G, Besson F. Interactions of Triton X-100 with sphingomyelin and 
phosphatidylcholine monolayers: influence of the cholesterol content. Colloids and 
Surfaces B: Biointerfaces. 2008 Oct 15;66(2):163-7. 
64 
  
126. Miyanishi, M., Tada, K., Koike, M., Uchiyama, Y., Kitamura, T., & Nagata, S. 
(2007). Identification of Tim4 as a phosphatidylserine receptor. Nature, 450(7168), 435. 
127. Tkach, M., & Thery, C. (2016). Communication by extracellular vesicles: where we 
are and where we need to go. Cell, 164(6), 1226-1232. 
128. Singer, S. J. (1992). Intercellular communication and cell-cell adhesion. Science, 
255(5052), 1671-1677. 
129. Mathivanan, S., Ji, H., & Simpson, R. J. (2010). Exosomes: extracellular organelles 
important in intercellular communication. Journal of proteomics, 73(10), 1907-1920. 
130. Andaloussi, S. E., Mäger, I., Breakefield, X. O., & Wood, M. J. (2013). Extracellular 
vesicles: biology and emerging therapeutic opportunities. Nature reviews Drug discovery, 
12(5), 347. 
131. Gatti, S., Bruno, S., Deregibus, M. C., Sordi, A., Cantaluppi, V., Tetta, C., & 
Camussi, G. (2011). Microvesicles derived from human adult mesenchymal stem cells 
protect against ischaemia–reperfusion-induced acute and chronic kidney injury. 
Nephrology Dialysis Transplantation, 26(5), 1474-1483. 
132. Royo, F., Schlangen, K., Palomo, L., Gonzalez, E., Conde-Vancells, J., Berisa, A., 
... & Falcon-Perez, J. M. (2013). Transcriptome of extracellular vesicles released by 
hepatocytes. PloS one, 8(7), e68693. 
133. Chivet, M., Hemming, F., Fraboulet, S., & Sadoul, R. (2012). Emerging role of 
neuronal exosomes in the central nervous system. Frontiers in physiology, 3, 145. 
134. Alexander, M., Hu, R., Runtsch, M. C., Kagele, D. A., Mosbruger, T. L., 
Tolmachova, T., ... & O’Connell, R. M. (2015). Exosome-delivered microRNAs modulate 
the inflammatory response to endotoxin. Nature communications, 6, 7321. 
135. Kim, S. H., Bianco, N., Menon, R., Lechman, E. R., Shufesky, W. J., Morelli, A. E., 
& Robbins, P. D. (2006). Exosomes derived from genetically modified DC expressing FasL 
are anti-inflammatory and immunosuppressive. Molecular therapy, 13(2), 289-300. 
136. McDonald, M. K., Tian, Y., Qureshi, R. A., Gormley, M., Ertel, A., Gao, R., ... & Ajit, 
S. K. (2014). Functional significance of macrophage-derived exosomes in inflammation 
and pain. PAIN®, 155(8), 1527-1539. 
137. Bretz, N. P., Ridinger, J., Rupp, A. K., Rimbach, K., Keller, S., Rupp, C., ... & 
Sammar, M. (2013). Body fluid exosomes promote secretion of inflammatory cytokines in 
monocytic cells via Toll-like receptor signaling. Journal of Biological Chemistry, 288(51), 
36691-36702. 
138. Zhao, H., Shang, Q., Pan, Z., Bai, Y., Li, Z., Zhang, H., ... & Wang, Q. (2018). 
Exosomes from adipose-derived stem cells attenuate adipose inflammation and obesity 
through polarizing M2 macrophages and beiging in white adipose tissue. Diabetes, 67(2), 
235-247. 
139. Song, J., Huang, J., Chen, X., Teng, X., Song, Z., Xing, Y., ... & Hu, S. (2016). 
Donor-derived exosomes induce specific regulatory T cells to suppress immune 
inflammation in the allograft heart. Scientific reports, 6, 20077. 
140. Marcilla, A., Martin-Jaular, L., Trelis, M., de Menezes-Neto, A., Osuna, A., Bernal, 
D., ... & del Portillo, H. A. (2014). Extracellular vesicles in parasitic diseases. Journal of 
extracellular vesicles, 3(1), 25040. 
141. Anderson, H. C., Mulhall, D., & Garimella, R. (2010). Role of extracellular 
membrane vesicles in the pathogenesis of various diseases, including cancer, renal 
diseases, atherosclerosis, and arthritis. Laboratory investigation, 90(11), 1549. 
142. Rak, J., & Guha, A. (2012). Extracellular vesicles–vehicles that spread cancer 
genes. Bioessays, 34(6), 489-497. 
143. Boulanger, C. M., Loyer, X., Rautou, P. E., & Amabile, N. (2017). Extracellular 
vesicles in coronary artery disease. Nature reviews cardiology, 14(5), 259. 
65 
  
144. Amabile, N., Rautou, P. E., Tedgui, A., & Boulanger, C. M. (2010, November). 
Microparticles: key protagonists in cardiovascular disorders. In Seminars in thrombosis and 
hemostasis (Vol. 36, No. 08, pp. 907-916). © Thieme Medical Publishers. 
145. Withrow, J., Murphy, C., Liu, Y., Hunter, M., Fulzele, S., & Hamrick, M. W. (2016). 
Extracellular vesicles in the pathogenesis of rheumatoid arthritis and osteoarthritis. Arthritis 
Research & Therapy, 18(1), 286. 
146. Moon, P. G., Lee, J. E., Cho, Y. E., Lee, S. J., Jung, J. H., Chae, Y. S., ... & Baek, 
M. C. (2016). Identification of developmental endothelial locus-1 on circulating extracellular 
vesicles as a novel biomarker for early breast cancer detection. Clinical Cancer Research, 
22(7), 1757-1766. 
147. Wang, B., Zhuang, X., Deng, Z. B., Jiang, H., Mu, J., Wang, Q., ... & Yan, J. (2014). 
Targeted drug delivery to intestinal macrophages by bioactive nanovesicles released from 
grapefruit. Molecular Therapy, 22(3), 522-534. 
148. Wang, Q., Ren, Y., Mu, J., Egilmez, N. K., Zhuang, X., Deng, Z., ... & Zhang, H. G. 
(2015). Grapefruit-derived nanovectors use an activated leukocyte trafficking pathway to 
deliver therapeutic agents to inflammatory tumor sites. Cancer research, 75(12), 2520-
2529. 
149. Wang, Q., Zhuang, X., Mu, J., Deng, Z. B., Jiang, H., Zhang, L., ... & Zhang, H. G. 
(2013). Delivery of therapeutic agents by nanoparticles made of grapefruit-derived lipids. 
Nature communications, 4, 1867. 
150. Zhou, Q., Li, M., Wang, X., Li, Q., Wang, T., Zhu, Q., ... & Li, X. (2012). Immune-
related microRNAs are abundant in breast milk exosomes. International journal of 
biological sciences, 8(1), 118. 
151. Wolf, T., Baier, S. R., & Zempleni, J. (2015). The intestinal transport of bovine milk 
exosomes is mediated by endocytosis in human colon carcinoma Caco-2 cells and rat 
small intestinal IEC-6 cells. The Journal of nutrition, 145(10), 2201-2206. 
152. Sun, Q., Chen, X., Yu, J., Zen, K., Zhang, C. Y., & Li, L. (2013). Immune 
modulatory function of abundant immune-related microRNAs in microvesicles from bovine 
colostrum. Protein & cell, 4(3), 197-210. 
153. Zhou, F., Paz, H. A., Shu, J., Sadri, M., Juan, C. U. I., Fernando, S., & ZEMPLENI, 
J. (2018). Dietary Bovine Milk Exosomes Elicit Changes in Microbial Communities in 
C57BL/6 Mice. bioRxiv, 356048. 
154. Leiferman, A., Shu, J., Grove, R., Cui, J., Adamec, J., & Zempleni, J. (2018). A diet 
defined by its content of bovine milk exosomes and their RNA cargos has moderate effects 
on gene expression, amino acid profiles and grip strength in skeletal muscle in C57BL/6 
mice. The Journal of nutritional biochemistry, 59, 123-128. 
155. Manca, S., Upadhyaya, B., Mutai, E., Desaulniers, A. T., Cederberg, R. A., White, 
B. R., & Zempleni, J. (2018). Milk exosomes are bioavailable and distinct microRNA cargos 
have unique tissue distribution patterns. Scientific reports, 8(1), 11321. 
156. Nordgren, T. M., Heires, A. J., Zempleni, J., Swanson, B. J., Wichman, C., & 
Romberger, D. J. (2019). Bovine milk-derived extracellular vesicles enhance inflammation 
and promote M1 polarization following agricultural dust exposure in mice. The Journal of 
nutritional biochemistry, 64, 110-120. 
157. Munagala, R., Aqil, F., Jeyabalan, J., & Gupta, R. C. (2016). Bovine milk-derived 
exosomes for drug delivery. Cancer letters, 371(1), 48-61. 
158. Gebhardt, S., Lemar, L., Haytowitz, D., Pehrsson, P., Nickle, M., Showell, B., ... & 
Holden, J. (2008). USDA national nutrient database for standard reference, release 21. 
United States Department of AgricultureAgricultural Research Service. 
159. Csak, T., Ganz, M., Pespisa, J., Kodys, K., Dolganiuc, A., & Szabo, G. (2011). 
Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release 
danger signals to stimulate immune cells. Hepatology, 54(1), 133-144. 
66 
  
160. Nguyen, M. A., Favelyukis, S., Nguyen, A. K., Reichart, D., Scott, P. A., Jenn, A., 
... & Olefsky, J. M. (2007). A subpopulation of macrophages infiltrates hypertrophic adipose 
tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent 
pathways. Journal of Biological Chemistry, 282(48), 35279-35292. 
161. Reynolds, C. M., McGillicuddy, F. C., Harford, K. A., Finucane, O. M., Mills, K. H., 
& Roche, H. M. (2012). Dietary saturated fatty acids prime the NLRP 3 inflammasome via 
TLR 4 in dendritic cells—implications for diet‐induced insulin resistance. Molecular nutrition 
& food research, 56(8), 1212-1222. 
162. Shi, H., Kokoeva, M. V., Inouye, K., Tzameli, I., Yin, H., & Flier, J. S. (2006). TLR4 
links innate immunity and fatty acid–induced insulin resistance. The Journal of clinical 
investigation, 116(11), 3015-3025. 
163. Wen, H., Gris, D., Lei, Y., Jha, S., Zhang, L., Huang, M. T. H., ... & Ting, J. P. 
(2011). Fatty acid–induced NLRP3-ASC inflammasome activation interferes with insulin 
signaling. Nature immunology, 12(5), 408. 
164. Gianfrancesco, M. A., Dehairs, J., L'homme, L., Herinckx, G., Esser, N., Jansen, 
O., ... & Piette, J. (2019). Saturated fatty acids induce NLRP3 activation in human 
macrophages through K+ efflux resulting from phospholipid saturation and Na, K-ATPase 
disruption. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids. 
165. Li, X., Wang, L., Nguyen, T., & Zhang, Y. (2016). Enhanced endothelial 
permeability by free fatty acid due to lysosomal cathepsin B-mediated activation of Nlrp3 
inflammasome. The FASEB Journal, 30(1_supplement), 1198-2. 
166. Finucane, O. M., Lyons, C. L., Murphy, A. M., Reynolds, C. M., Klinger, R., Healy, 
N. P., ... & O’reilly, M. E. (2015). Monounsaturated fatty acid–enriched high-fat diets 
impede adipose NLRP3 inflammasome–mediated IL-1β secretion and insulin resistance 
despite obesity. Diabetes, 64(6), 2116-2128. 
167. Boden, G., & Shulman, G. I. (2002). Free fatty acids in obesity and type 2 diabetes: 
defining their role in the development of insulin resistance and β‐cell dysfunction. European 
journal of clinical investigation, 32, 14-23. 
168. Luo, X., Yang, Y., Shen, T., Tang, X., Xiao, Y., Zou, T., ... & Ling, W. (2012). 
Docosahexaenoic acid ameliorates palmitate-induced lipid accumulation and inflammation 
through repressing NLRC4 inflammasome activation in HepG2 cells. Nutrition & 
metabolism, 9(1), 34. 
169. Robinson, D. R., Urakaze, M., Huang, R., Taki, H., Sugiyama, E., Knoell, C. T., ... 
& Auron, P. E. (1996). Dietary marine lipids suppress continuous expression of interleukin-
1β gene transcription. Lipids, 31(1), S23-S31. 
170. Lin, C., Chao, H., Li, Z., Xu, X., Liu, Y., Bao, Z., ... & Liu, N. (2017). Omega-3 fatty 
acids regulate NLRP3 inflammasome activation and prevent behavior deficits after 
traumatic brain injury. Experimental neurology, 290, 115-122. 
171. Lee, K. R., Midgette, Y., & Shah, R. (2018). Fish Oil Derived Omega 3 Fatty Acids 
Suppress Adipose NLRP3 Inflammasome Signaling in Human Obesity. Journal of the 
Endocrine Society, 3(3), 504-515. 
172. Shen, L., Yang, Y., Ou, T., Key, C. C. C., Tong, S. H., Sequeira, R. C., ... & 
Shewale, S. V. (2017). Dietary PUFAs attenuate NLRP3 inflammasome activation via 
enhancing macrophage autophagy. Journal of lipid research, 58(9), 1808-1821. 
173. Cipollina, C., Di Vincenzo, S., Piparo, D. L., & Pace, E. (2017). Late Breaking 
Abstract-17-oxo-DHA inhibits the NLRP3 inflammasome downstream of mitochondrial 
ROS and ERK pathway. 
174. Tsai, P. Y., Ka, S. M., Chang, J. M., Chen, H. C., Shui, H. A., Li, C. Y., ... & Chen, 
A. (2011). Epigallocatechin-3-gallate prevents lupus nephritis development in mice via 
enhancing the Nrf2 antioxidant pathway and inhibiting NLRP3 inflammasome activation. 
Free Radical Biology and Medicine, 51(3), 744-754. 
67 
  
175. Yin, H., Guo, Q., Li, X., Tang, T., Li, C., Wang, H., ... & Yi, F. (2018). Curcumin 
suppresses IL-1β secretion and prevents inflammation through inhibition of the NLRP3 
inflammasome. The Journal of Immunology, 200(8), 2835-2846. 
176. Wang, X., Zhang, Z. F., Zheng, G. H., Wang, A. M., Sun, C. H., Qin, S. P., ... & 
Zheng, Y. L. (2017). The inhibitory effects of purple sweet potato color on hepatic 
inflammation is associated with restoration of NAD+ levels and attenuation of NLRP3 
inflammasome activation in high-fat-diet-treated mice. Molecules, 22(8), 1315. 
177. Chuang, C. C., & McIntosh, M. K. (2011). Potential mechanisms by which 
polyphenol-rich grapes prevent obesity-mediated inflammation and metabolic diseases. 
Annual review of nutrition, 31, 155-176. 
178. Terra, X., Montagut, G., Bustos, M., Llopiz, N., Ardèvol, A., Bladé, C., ... & Blay, 
M. (2009). Grape-seed procyanidins prevent low-grade inflammation by modulating 
cytokine expression in rats fed a high-fat diet. The Journal of nutritional biochemistry, 20(3), 
210-218. 
179. Dou, W., Zhang, J., Ren, G., Ding, L., Sun, A., Deng, C., ... & Wang, Z. (2014). 
Mangiferin attenuates the symptoms of dextran sulfate sodium-induced colitis in mice via 
NF-κB and MAPK signaling inactivation. International immunopharmacology, 23(1), 170-
178. 
180. Song, J., Li, J., Hou, F., Wang, X., & Liu, B. (2015). Mangiferin inhibits endoplasmic 
reticulum stress-associated thioredoxin-interacting protein/NLRP3 inflammasome 
activation with regulation of AMPK in endothelial cells. Metabolism, 64(3), 428-437. 
181. Pan, C. W., Pan, Z. Z., Hu, J. J., Chen, W. L., Zhou, G. Y., Lin, W., ... & Xu, C. L. 
(2016). Mangiferin alleviates lipopolysaccharide and D-galactosamine-induced acute liver 
injury by activating the Nrf2 pathway and inhibiting NLRP3 inflammasome activation. 
European journal of pharmacology, 770, 85-91. 
182. Fan, K., Ma, J., Xiao, W., Chen, J., Wu, J., Ren, J., ... & Yu, B. (2017). Mangiferin 
attenuates blast-induced traumatic brain injury via inhibiting NLRP3 inflammasome. 
Chemico-biological interactions, 271, 15-23. 
183. Qu, S., Wang, W., Li, D., Li, S., Zhang, L., Fu, Y., & Zhang, N. (2017). Mangiferin 
inhibits mastitis induced by LPS via suppressing NF-ĸB and NLRP3 signaling pathways. 
International immunopharmacology, 43, 85-90. 
184. Vaszilesin, C. G., Dan, M. L., Duca, D. A., & Labosel, M. A. (2017). Resveratrol as 
corrosion inhibitor for metals in wine and food industries. In 22nd International Symposium 
on Analytical and Environmental Problems. 
185. Chang, Y. P., Ka, S. M., Hsu, W. H., Chen, A., Chao, L. K., Lin, C. C., ... & Chiu, 
Y. C. (2015). Resveratrol inhibits NLRP3 inflammasome activation by preserving 
mitochondrial integrity and augmenting autophagy. Journal of cellular physiology, 230(7), 
1567-1579. 
186. He, Q., Li, Z., Wang, Y., Hou, Y., Li, L., & Zhao, J. (2017). Resveratrol alleviates 
cerebral ischemia/reperfusion injury in rats by inhibiting NLRP3 inflammasome activation 
through Sirt1-dependent autophagy induction. International immunopharmacology, 50, 
208-215. 
187. Yu, C., He, Q., Zheng, J., Li, L. Y., Hou, Y. H., & Song, F. Z. (2017). Sulforaphane 
improves outcomes and slows cerebral ischemic/reperfusion injury via inhibition of NLRP3 
inflammasome activation in rats. International immunopharmacology, 45, 74-78. 
188. Yang, G., Yeon, S. H., Lee, H. E., Kang, H. C., Cho, Y. Y., Lee, H. S., & Lee, J. Y. 
(2018). Suppression of NLRP3 inflammasome by oral treatment with sulforaphane 
alleviates acute gouty inflammation. Rheumatology, 57(4), 727-736. 
189. Hsieh, C. Y., Li, L. H., Rao, Y. K., Ju, T. C., Nai, Y. S., Chen, Y. W., & Hua, K. F. 
(2019). Mechanistic insight into the attenuation of gouty inflammation by Taiwanese green 




190. Wang, L., Yu, Z., Wei, C., Zhang, L., Song, H., Chen, B., & Yang, Q. (2017). Huaier 
aqueous extract protects against dextran sulfate sodium-induced experimental colitis in 
mice by inhibiting NLRP3 inflammasome activation. Oncotarget, 8(20), 32937. 
191. Lavi, I., Levinson, D., Peri, I., Nimri, L., Hadar, Y., & Schwartz, B. (2010). Orally 
administered glucans from the edible mushroom Pleurotus pulmonarius reduce acute 
inflammation in dextran sulfate sodium-induced experimental colitis. British journal of 
nutrition, 103(3), 393-402. 
192. Wu, S. J., Lu, T. M., Lai, M. N., & Ng, L. T. (2013). Immunomodulatory activities of 
medicinal mushroom Grifola frondosa extract and its bioactive constituent. The American 
journal of Chinese medicine, 41(01), 131-144. 
193. Han, J. M., Lee, E. K., Gong, S. Y., Sohng, J. K., Kang, Y. J., & Jung, H. J. (2019). 
Sparassis crispa exerts anti-inflammatory activity via suppression of TLR-mediated NF-κB 
and MAPK signaling pathways in LPS-induced RAW264. 7 macrophage cells. Journal of 
ethnopharmacology, 231, 10-18. 
194. Dudhgaonkar, S., Thyagarajan, A., & Sliva, D. (2009). Suppression of the 
inflammatory response by triterpenes isolated from the mushroom Ganoderma lucidum. 
International immunopharmacology, 9(11), 1272-1280. 
195. Jedinak, A., Dudhgaonkar, S., Wu, Q. L., Simon, J., & Sliva, D. (2011). Anti-
inflammatory activity of edible oyster mushroom is mediated through the inhibition of NF-
κB and AP-1 signaling. Nutrition journal, 10(1), 52. 
196. Chang, H. H., Hsieh, K. Y., Yeh, C. H., Tu, Y. P., & Sheu, F. (2010). Oral 
administration of an Enoki mushroom protein FVE activates innate and adaptive immunity 
and induces anti-tumor activity against murine hepatocellular carcinoma. International 
immunopharmacology, 10(2), 239-246. 
197. Ye, M., Liu, J. K., Lu, Z. X., Zhao, Y., Liu, S. F., Li, L. L., ... & Cao, Y. (2005). 
Grifolin, a potential antitumor natural product from the mushroom Albatrellus confluens, 
inhibits tumor cell growth by inducing apoptosis in vitro. FEBS letters, 579(16), 3437-3443. 
198. Youn, M. J., Kim, J. K., Park, S. Y., Kim, Y., Kim, S. J., Lee, J. S., ... & Kim, K. Y. 
(2008). Chaga mushroom (Inonotus obliquus) induces G0/G1 arrest and apoptosis in 
human hepatoma HepG2 cells. World Journal of Gastroenterology: WJG, 14(4), 511. 
199. Koyama, Y., Katsuno, Y., Miyoshi, N., Hayakawa, S., Mita, T., Muto, H., ... & 
Isemura, M. (2002). Apoptosis induction by lectin isolated from the mushroom Boletopsis 
leucomelas in U937 cells. Bioscience, biotechnology, and biochemistry, 66(4), 784-789. 
200. Wang, F. F., Shi, C., Yang, Y., Fang, Y., Sheng, L., & Li, N. (2018). Medicinal 
mushroom Phellinus igniarius induced cell apoptosis in gastric cancer SGC-7901 through 
a mitochondria-dependent pathway. Biomedicine & Pharmacotherapy, 102, 18-25. 
201. Wang, Y., Xu, G., Tang, X., & Chen, H. (2017). Polysaccharide lentinan extracted 
from the stipe of Lentinus edodes mushroom exerts anticancer activities through the 
transcriptional regulation of cell cycle progression and metastatic markers in human colon 
cancer cells. The FASEB Journal, 31(1_supplement), lb391-lb391. 
202. Grube, B. J., Eng, E. T., Kao, Y. C., Kwon, A., & Chen, S. (2001). White button 
mushroom phytochemicals inhibit aromatase activity and breast cancer cell proliferation. 
The Journal of nutrition, 131(12), 3288-3293. 
203. Guo, J., Zhu, T., Collins, L., Xiao, Z. X. J., Kim, S. H., & Chen, C. Y. (2007). 
Modulation of lung cancer growth arrest and apoptosis by Phellinus Linteus. Molecular 
Carcinogenesis: Published in cooperation with the University of Texas MD Anderson 
Cancer Center, 46(2), 144-154. 
204. Hetland, G., Johnson, E., Lyberg, T., Bernardshaw, S., Tryggestad, A. M. A., & 
Grinde, B. (2008). Effects of the medicinal mushroom Agaricus blazei Murill on immunity, 
infection and cancer. Scandinavian journal of immunology, 68(4), 363-370. 
205. Cheung, L. M., & Cheung, P. C. (2005). Mushroom extracts with antioxidant activity 
against lipid peroxidation. Food Chemistry, 89(3), 403-409. 
69 
  
206. Turkoglu, A., Duru, M. E., Mercan, N., Kivrak, I., & Gezer, K. (2007). Antioxidant 
and antimicrobial activities of Laetiporus sulphureus (Bull.) Murrill. Food Chemistry, 101(1), 
267-273. 
207. Wu, D., Pae, M., Ren, Z., Guo, Z., Smith, D., & Meydani, S. N. (2007). Dietary 
supplementation with white button mushroom enhances natural killer cell activity in 
C57BL/6 mice. The Journal of nutrition, 137(6), 1472-1477. 
208. Dai, X., Stanilka, J. M., Rowe, C. A., Esteves, E. A., Nieves Jr, C., Spaiser, S. J., 
... & Percival, S. S. (2015). Consuming Lentinula edodes (Shiitake) mushrooms daily 
improves human immunity: A randomized dietary intervention in healthy young adults. 
Journal of the American College of Nutrition, 34(6), 478-487. 
209. Dalloul, R. A., Lillehoj, H. S., Lee, J. S., Lee, S. H., & Chung, K. S. (2006). 
Immunopotentiating effect of a Fomitella fraxinea-derived lectin on chicken immunity and 
resistance to coccidiosis. Poultry science, 85(3), 446-451. 
210. Jayakumar, T., Ramesh, E., & Geraldine, P. (2006). Antioxidant activity of the 
oyster mushroom, Pleurotus ostreatus, on CCl4-induced liver injury in rats. Food and 
Chemical Toxicology, 44(12), 1989-1996. 
211. Shah, S. R., Ukaegbu, C. I., Hamid, H. A., & Alara, O. R. (2018). Evaluation of 
antioxidant and antibacterial activities of the stems of Flammulina velutipes and 
Hypsizygus tessellatus (white and brown var.) extracted with different solvents. Journal of 
Food Measurement and Characterization, 12, 1947-1961. 
212. Dinarello, C. A. (1998). Interleukin‐1β, Interleukin‐18, and the Interleukin‐1β 
Converting Enzyme a. Annals of the New York Academy of Sciences, 856(1), 1-11. 
213. Hong, P., Li, F. X., Gu, R. N., Fang, Y. Y., Lai, L. Y., Wang, Y. W., ... & Zhang, H. 
F. (2018). Inhibition of NLRP3 inflammasome ameliorates cerebral ischemia-reperfusion 
injury in diabetic mice. Neural plasticity, 2018. 
214. Yin, J., Zhao, F., Chojnacki, J. E., Fulp, J., Klein, W. L., Zhang, S., & Zhu, X. (2018). 
NLRP3 inflammasome inhibitor ameliorates amyloid pathology in a mouse model of 
Alzheimer’s disease. Molecular neurobiology, 55(3), 1977-1987. 
215. Jansen, T. L., Klück, V., Janssen, M., Comarniceanu, A., Efdé, M., Scribner, C. L., 
... & Joosten, L. A. (2019). P160 The first phase 2A proof-of-concept study of a selective 
NLRP3 inflammasome inhibitor, dapansutrile™(OLT1177™), in acute gout.  
216. Spreafico, R., Ricciardi‐Castagnoli, P., & Mortellaro, A. (2010). The controversial 
relationship between NLRP3, alum, danger signals and the next‐generation adjuvants. 
European journal of immunology, 40(3), 638-642. 
217. Jo, E. K., Kim, J. K., Shin, D. M., & Sasakawa, C. (2016). Molecular mechanisms 
regulating NLRP3 inflammasome activation. Cellular & molecular immunology, 13(2), 148. 
218. He, Y., Zeng, M. Y., Yang, D., Motro, B., & Núñez, G. (2016). NEK7 is an essential 
mediator of NLRP3 activation downstream of potassium efflux. Nature, 530(7590), 354. 
219. Leiferman, A., Shu, J., Grove, R., Cui, J., Adamec, J., & Zempleni, J. (2018). A diet 
defined by its content of bovine milk exosomes and their RNA cargos has moderate effects 
on gene expression, amino acid profiles and grip strength in skeletal muscle in C57BL/6 
mice. The Journal of nutritional biochemistry, 59, 123-128.  
220. Baier, S. R., Nguyen, C., Xie, F., Wood, J. R., & Zempleni, J. (2014). MicroRNAs 
are absorbed in biologically meaningful amounts from nutritionally relevant doses of cow 
milk and affect gene expression in peripheral blood mononuclear cells, HEK-293 kidney 
cell cultures, and mouse livers. The Journal of nutrition, 144(10), 1495-1500. 
221. Wasser, S. P., & Weis, A. L. (1999). Therapeutic effects of substances occurring 
in higher Basidiomycetes mushrooms: a modern perspective. Critical Reviews™ in 
Immunology, 19(1). 
222. Huang, T. T., Ojcius, D. M., Young, J. D., Wu, Y. H., Ko, Y. F., Wong, T. Y., ... & 
Lai, H. C. (2012). The anti-tumorigenic mushroom Agaricus blazei Murill enhances IL-1β 
70 
  
production and activates the NLRP3 inflammasome in human macrophages. PLoS One, 
7(7), e41383. 
223. Yang, Y., Inatsuka, C., Disis, M. L., & Lu, H. (2013). Protein-bound polysaccharide 
induces IL-1β via NLRP3 inflammasome activation. 
224. Liu, W., Ji, J., Chen, Z. Z., & Yan, H. (2015). Lentinan plays synergistic effects in 
paclitaxel-induced A549 cell apoptosis via activating ROS-TXNIP-NLRP3 signal. Journal 
of Cellular and Molecular Medicine, 19, 1949-1955. 
225. Li, X., Jin, Q., Zhang, Y., Wu, Y. L., Jin, C. M., Cui, B. W., ... & Yang, H. X. (2018). 
Inhibition of P2X7R–NLRP3 Inflammasome Activation by Pleurotus citrinopileatus: A 
Possible Protective Role in Alcoholic Hepatosteatosis. Journal of agricultural and food 
chemistry, 66(50), 13183-13190. 
226. Tian, T., Zhu, Y. L., Zhou, Y. Y., Liang, G. F., Wang, Y. Y., Hu, F. H., & Xiao, Z. D. 
(2014). Exosome uptake through clathrin-mediated endocytosis and macropinocytosis and 
mediating miR-21 delivery. Journal of Biological Chemistry, 289(32), 22258-22267. 
227. Ahn, H., Jeon, E., Kim, J. C., Kang, S. G., Yoon, S. I., Ko, H. J., ... & Lee, G. S. 
(2017). Lentinan from shiitake selectively attenuates AIM2 and non-canonical 
inflammasome activation while inducing pro-inflammatory cytokine production. Scientific 
reports, 7(1), 1314. 
228. Zempleni, J., Aguilar-Lozano, A., Sadri, M., Sukreet, S., Manca, S., Wu, D., ... & 
Mutai, E. (2016). Biological activities of extracellular vesicles and their cargos from bovine 
and human milk in humans and implications for infants. The Journal of nutrition, 147(1), 3-
10. 
229. Izumi, H., Tsuda, M., Sato, Y., Kosaka, N., Ochiya, T., Iwamoto, H., ... & Takeda, 
Y. (2015). Bovine milk exosomes contain microRNA and mRNA and are taken up by 
human macrophages. Journal of dairy science, 98(5), 2920-2933. 
230. Wyss-Coray, T., & Mucke, L. (2002). Inflammation in neurodegenerative disease—
a double-edged sword. Neuron, 35(3), 419-432. 
231. Davis, B. K., Wen, H., & Ting, J. P. Y. (2011). The inflammasome NLRs in 
immunity, inflammation, and associated diseases. Annual review of immunology, 29, 707-
735. 
232. Braddock, M., & Quinn, A. (2004). Targeting IL-1 in inflammatory disease: new 
opportunities for therapeutic intervention. Nature reviews Drug discovery, 3(4), 330. 
233. Yan, Y., Jiang, W., Liu, L., Wang, X., Ding, C., Tian, Z., & Zhou, R. (2015). 
Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. 
Cell, 160(1-2), 62-73. 
234. Hernandez-Cuellar, E., Tsuchiya, K., Hara, H., Fang, R., Sakai, S., Kawamura, I., 
... & Mitsuyama, M. (2012). Cutting edge: nitric oxide inhibits the NLRP3 inflammasome. 
The Journal of Immunology, 189(11), 5113-5117. 
235. Mao, K., Chen, S., Chen, M., Ma, Y., Wang, Y., Huang, B., ... & Li, J. (2013). Nitric 
oxide suppresses NLRP3 inflammasome activation and protects against LPS-induced 
septic shock. Cell research, 23(2), 201. 
236. Ward, R., Li, W., Abdul, Y., Jackson, L., Dong, G., Jamil, S., ... & Ergul, A. (2019). 
NLRP3 inflammasome inhibition with MCC950 improves diabetes-mediated cognitive 
impairment and vasoneuronal remodeling after ischemia. Pharmacological research, 142, 
237-250. 
237. Jiang, W., Li, M., He, F., & Zhu, L. (2019). Inhibition of NLRP3 inflammasome 
attenuates spinal cord injury‐induced lung injury in mice. Journal of cellular physiology, 
234(5), 6012-6022. 
238. Wang, L., Schmidt, S., Larsen, P. P., Meyer, J. H., Roush, W. R., Latz, E., ... & 
Krohne, T. U. (2019). Efficacy of novel selective NLRP3 inhibitors in human and murine 
retinal pigment epithelial cells. Journal of Molecular Medicine, 1-10. 
71 
  
239. Zhou, X., Wu, Y., Ye, L., Wang, Y., Zhang, K., Wang, L., ... & Chen, Y. (2019). 
Aspirin alleviates endothelial gap junction dysfunction through inhibition of NLRP3 
inflammasome activation in LPS-induced vascular injury. Acta Pharmaceutica Sinica B. 
240. Han, X., Sun, S., Sun, Y., Song, Q., Zhu, J., Song, N., ... & Lu, M. (2019). Small 
molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and 
autophagy: implications for Parkinson disease. Autophagy, 1-22. 
241. Chen, C., Wei, Y. Z., He, X. M., Li, D. D., Wang, G., Li, J. J., & Zhang, F. (2019). 
Naringenin produces neuroprotection against LPS-induced dopamine neurotoxicity via the 
inhibition of microglial NLRP3 inflammasome activation. Frontiers in Immunology, 10, 936. 
242. Lee, E. H., Shin, J. H., Kim, S. S., Lee, H., Yang, S. R., & Seo, S. R. (2019). Laurus 
nobilis leaf extract controls inflammation by suppressing NLRP3 inflammasome activation. 
Journal of cellular physiology, 234(5), 6854-6864. 
243. Zhang, M., Viennois, E., Prasad, M., Zhang, Y., Wang, L., Zhang, Z., ... & Merlin, 
D. (2016). Edible ginger-derived nanoparticles: A novel therapeutic approach for the 
prevention and treatment of inflammatory bowel disease and colitis-associated cancer. 
Biomaterials, 101, 321-340. 
244. Zhuang, X., Deng, Z. B., Mu, J., Zhang, L., Yan, J., Miller, D., ... & Zhang, H. G. 
(2015). Ginger-derived nanoparticles protect against alcohol-induced liver damage. 
Journal of extracellular vesicles, 4(1), 28713. 
245. Zhou, F., Paz, H. A., Sadri, M., Fernando, S. C., & Zempleni, J. (2017). A diet 
defined by its content of bovine milk exosomes alters the composition of the intestinal 
microbiome in C57BL/6 mice. The FASEB Journal, 31(1_supplement), 965-24. 
246. Li, B., Hock, A., Wu, R. Y., Minich, A., Botts, S. R., Lee, C., ... & Zani, A. (2019). 
Bovine milk-derived exosomes enhance goblet cell activity and prevent the development 
of experimental necrotizing enterocolitis. PloS one, 14(1), e0211431. 
247. Chen, X., Zhou, Y., & Yu, J. (2019). Exosome-like Nanoparticles from Ginger 
Rhizomes Inhibited NLRP3 Inflammasome Activation. Molecular pharmaceutics. 
248. Teng, Y., Ren, Y., Sayed, M., Hu, X., Lei, C., Kumar, A., ... & Sundaram, K. (2018). 
Plant-derived exosomal MicroRNAs shape the gut microbiota. Cell host & microbe, 24(5), 
 
 
